SMI Vantage Limited invests in the Whisky Cask Club

Capitalising on the rapid growth in the buying and trading of Whisky Casks to discerning investors and consumersCombining the industry-leading knowledge and expertise of the Whisky Cask Club founder, Alex Knight and SMI’s Mark Bedingham’s, the former regional Managing Director (Asia Pacific) of Moet Hennesy, extensive global industry knowledgeSINGAPORE, Aug 15, 2024 - (ACN Newswire via SeaPRwire.com) - SMI Vantage Limited (SGX: Y45) (“SMI” or the “Company”), a Singapore-based investment and management company listed on the mainboard of the SGX is pleased to announce the acquisition of a controlling interest in Whisky Cask Club (“WCC”). This move marks a significant step in SMI Vantage's strategy of investing in innovative businesses with high growth potential.Whisky Cask Club is a premier brokerage firm based in Singapore, specialising in the investment and trading of casks of rare and ultra-premium whisky. With over 50 years of combined experience in the Scottish whisky industry, the company partners with exclusive suppliers to provide clients access to some of the most sought-after casks available in the market.Mark Bedingham, President and CEO of SMI Vantage, stated, "This is a major acquisition which is transformative for SMI Vantage and is expected to become the leading growth contributor for SMI driving rapid increase in revenues and the overall profitability of the Group. The partnership with Alex Knight will allow considerable growth around the region and beyond from its Singapore base and aligns perfectly with our strategy to diversify into high growth businesses that are immediately revenue and profit generating."Alexander Knight, CEO and Co-Founder of Whisky Cask Club remarked, "Joining forces with SMI Vantage and partnering with its CEO Mark Bedingham will create the conditions for acceleration of the growth path that WCC has been on for the last few years. With Mark’s help, we will look to open several major new international markets and bring the excitement and pleasure of investing in, as well as experiencing, the extraordinary whiskies that we can bring to the world."https://links.sgx.com/1.0.0/corporate-announcements/2RJ2U427QZN8ZI47/815867_20240815_SMI%20Invests%20in%20the%20Whisky%20Cask%20Club.pdf About SMI VantageSMI Vantage Limited is an investment and management company focused on capitalising on strong trends in the new economy, including Food and Beverage related businesses, technology-based SaaS services and other high-tech platforms. Listed on the Main Board of the Singapore Stock Exchange, SMI Vantage Limited has a highly capable and experienced management team with a proven track record in building strong business partnerships and alliances.Whisky Cask ClubThe Whisky Cask Club has a combined 50 years of experience in the Scottish whisky industry. We have partnered with some of the most exclusive suppliers of Scottish whisky to give our clients the most sought-after casks of whisky in the market. In order to be able to sell our clients casks of ultra high-end whisky, the Cask Club has partnered with ACEO Spirits and Whisky who are our official UK Duty representative.For media queries, please reach out to:Waterbrooks Consultants Pte LtdWayne Koo - wayne.koo@waterbrooks.com.sg +65 9338-8166Derek Yeo – derek@waterbrooks.com.sg +65 9791-4707Proud Investor Relations partner:www.waterbrooks.com.sg www.shareinvestorholdings.com www.alphainvestholdings.com Copyright 2024 ACN Newswire via SeaPRwire.com.

16 8 月, 2024

「從灣區啓航：”南海I號”與海上絲綢之路」展覽開幕

香港, 2024年8月16日 - (亞太商訊 via SeaPRwire.com) – 由發展局、國家文物局和澳門特別行政區政府社會文化司合辦的「從灣區啓航：『南海I號』與海上絲綢之路」展覽於八月十五日舉行開幕禮。展覽展出「南海I號」遠洋商船的出土文物及粵港澳三地的相關文物，以展示粵港澳大灣區在海上絲綢之路的角色。開幕禮由發展局局長甯漢豪、中國文物交流中心副主任周宇、廣東省文物考古研究院院長曹勁和澳門特別行政區政府文化局副局長鄭繼明主持。「南海I號」是南宋時期的商舶，至二○○七年被打撈出水，是迄今考古發現保存最完整的古代遠洋商船。「南海I號」出土大量文物，主要有瓷器、銅鐵器、金銀器、漆木器等，其數量、形制、工藝和造型，在南宋時期的考古材料中，均屬罕見。考古專家推斷「南海I號」於南宋淳熙十年（1183年）或不久以後，在廣東往南海的航道上沉沒。是次展出的255項展品中，有來自「南海I號」的南海窰醬釉「淳熙十年」印文四繫罐、景德鎮窰青白釉印花枝梅紋花口碗、龍泉窰青釉刻劃蓮紋折腰花口碟、金單頂鏈犀角形錐筒飾項鍊、鑲寶石空心金鐲等。來自粵港澳三地的展品則包括廣州南越國宮署遺址出土的宋代湖田窰青白釉墨書「公使」款碗底殘件、香港聖山遺址出土的宋代青黃釉龍紋六繫罐、澳門聖保祿學院遺址出土的明代景德鎮窰青花象首軍持等。展覽於尖沙咀海防道九龍公園香港文物探知館舉行，展期由八月十六日至明年二月十二日，免費入場。有關展覽籌備過程的短片，已上載發展局古物古蹟辦事處網頁（www.amo.gov.hk/tc/news/index_id_153.html?year=2024）。「從灣區啓航：『南海I號』與海上絲綢之路」展覽於八月十五日舉行開幕禮。圖示發展局局長甯漢豪（右二）、中國文物交流中心副主任周宇（左二）、廣東省文物考古研究院院長曹勁（右一）和澳門特別行政區政府文化局副局長鄭繼明（左一）主持開幕禮。「從灣區啓航：『南海I號』與海上絲綢之路」展覽於八月十五日舉行開幕禮。圖示發展局局長甯漢豪（左一）和中國文物交流中心副主任周宇（右三）及澳門特別行政區政府文化局副局長鄭繼明（右二）參觀展覽。「從灣區啓航：『南海I號』與海上絲綢之路」展覽於八月十五日舉行開幕禮。圖示發展局局長甯漢豪（左一）和中國文物交流中心副主任周宇（左二）及澳門特別行政區政府文化局副局長鄭繼明（左三）參觀展覽。南海窰醬釉「淳熙十年」(1183) 印文四繫罐，罐上印文對推斷「南海 I 號」沉沒時間至關重要。南宋(1127-1279)鑲寶石空心金鐲，「南海I號」出土，沙特阿拉伯利雅德也有類似的器物出土。南宋(1127-1279)龍泉窰青釉刻劃蓮紋折腰花口碟，「南海I號」出土 Copyright 2024 亞太商訊 via SeaPRwire.com.

16 8 月, 2024

卫龙美味公佈2024年中期業績

香港, 2024年8月16日 - (亞太商訊 via SeaPRwire.com) – 中國辣味休閒食品行業龍頭企業，卫龙美味全球控股有限公司（「卫龙美味」或「集團」）及附屬公司（「集團」）（香港聯交所股票代碼：09985）公佈截至2024年6月30日止六個月（「期內」）未經審核之中期業績。2024年上半年，全球不確定性因素增多背景下，中國經濟維持穩健增長勢頭。得益於以Z世代為首的年輕消費群體日益增高的消費意願，休閒食品產業的成長動力強勁。回顧期內，卫龙美味緊握多元化主流消費觀念帶來的零食領域的結構性機會，堅定「多品類大單品」產品策略並持續提升研發能力，積極開展線上線下組合式營銷活動以提升品牌影響力，全力推進全渠道策略落地實施，進而為消費者提供更滿意、更便利、更好的消費體驗。報告期內，卫龙美味經營策略收效明顯，業績持續向好，營收淨利實現雙位數增長。2024年上半年實現總收入約29.39億元（人民幣，下同），同比增長26.3%，主要得益於集團期內有效實施各項業務發展策略，特別是積極推進全渠道建設和品牌建設，線上線下收入均有穩步提升。受惠於期內產能利用率提升及部分原材料價格下降，集團錄得毛利為約14.62億元，同比增長32.2%，毛利率由去年同期47.5%提升2.3個百分點至49.8%。集團期內淨利潤同比大幅增長38.9%至約6.21億元。在收入及毛利率提升的推動下，淨利率較上年同期提升了1.9個百分點至21.1%。基於期內整體績效表現，集團董事會決議派發2024年中期股息每股人民幣0.16元（含稅，共計中期股息約3.76億元），約為2024年上半年淨利潤的60%，預計派付股息日期為2024年10月18日或前後。產品方面，集團堅持以消費者體驗為中心，堅持「多品類、大單品」產品策略，積極提升產品研發能力，持續挖掘年輕消費群體的消費喜好變化，先後推出「小魔女」香辣燒烤味魔芋素板筋，「小魔女」酸辣火鍋味魔芋素毛肚，及「脆火火」青檸味辣脆片等產品，進一步擴大產品組合，以滿足消費者多樣化、個性化等各方面的需求。品牌建設方面，集團持續加強品牌建設，積極通過開展線上線下組合式品牌及營銷活動加強與消費者的互動，以提升品牌影響力，譬如核心大單品「魔芋爽」的品牌傳播、「小魔女」IP動畫視頻、「榴蓮辣條」快閃店、「蛋仔派對」聯名親嘴燒等各種好玩有趣的營銷活動。集團積極打造與眾不同的品牌年輕化之路，以不斷增加品牌的活力和吸引力，讓品牌更貼近年輕消費群體的生活方式和消費習慣。渠道方面，集團積極推進全渠道策略的落地實施，在鞏固傳統零食渠道佈局的同時，緊握O2O、內容電商、零食量販店、倉儲會員店等新興渠道帶來的增長機遇。報告期內，集團深耕線上線下全渠道建設，與消費者建立了更加緊密的聯繫，提供了更便利的消費體驗。卫龙美味董事長劉衛平先生表示：「作為中國辣味休閒食品行業的領導者和先行者，集團堅持以更積極、更開放的心態擁抱多元化的消費喜好變化，積極加強品類創新和產品創新、推進年輕化多樣化的品牌建設、抓住新型渠道發展紅利的同時夯實傳統渠道、堅定產品創新和全渠道建設、堅持供應鏈品質與效率的有效提升，持續打造為消費者提供更多價值的辣味休閒食品龍頭企業。集團將繼續不忘初心、牢記使命，致力為消費者、客戶、股東、投資者、員工及社會創造最大的價值回報。」人民幣截至6月30日止六個月變動2024年2023年收入29.39億23.27億+26.3%毛利14.62億11.06億+32.2%毛利率49.8%47.5%+2.3個百分點期內利潤6.21億4.47億+38.9%淨利潤率21.1%19.2%+1.9個百分點每股基本盈利0.27元0.19元+42.1%中期股息 0.16元/普通股0.12元/普通股+33.3%- 完 -關於卫龙美味全球控股有限公司卫龙美味全球控股有限公司（「卫龙美味」）是中國領先的集研發、生產及銷售為一體的辣味休閒食品企業，擁有強勁的增長勢頭和頗具影響力的品牌。卫龙美味以傳統美食為基礎開創了中國調味面製品（俗稱「辣條」）行業，於2001年開創出第一根辣條，並引領了辣條行業標準建設。憑借出眾的品類拓展能力，本集團已成功擴展至蔬菜製品、豆製品及其它產品等品類，推出了包括魔芋爽、風吃海帶、溏心蛋等大單品。本集團又相繼推出麻辣辣條、魔芋素毛肚「小魔女」及辣脆片「脆火火」等新品，深受消費者的喜愛。卫龙美味是倍受中國年輕消費者喜愛的休閒食品品牌，擁有有效觸達年輕消費者的全渠道銷售及經銷網絡。2024年我們榮獲FBIF WOW食品創新獎「年度創新休閒零食獎」，同時亦獲得「胡潤國潮品牌百強榜」獎項。如欲獲得更多資訊，請瀏覽https://www.weilongshipin.com/。 Copyright 2024 亞太商訊 via SeaPRwire.com.

16 8 月, 2024

越秀房產基金整體經營穩定 實現收入逾人民幣10億元

香港, 2024年8月15日 - (亞太商訊 via SeaPRwire.com) – 越秀房地產投資信託基金（「越秀房產基金」，連同越秀房託資產管理有限公司，統稱「基金」；股份代號：405）公佈其截至2024年6月30日止六個月之中期業績。越秀房產基金管理團隊：主席兼行政總裁及執行董事林德良先生（左二）、副行政總裁及執行董事區海晶女士（左三）、財務總監關志輝先生（左一）、投資者關係總監姜永進先生（左四）2024年中期業績摘要：- 整體經營穩定，收入總額為人民幣10.34億元（2023年同期：人民幣10.61億元）。- 中期分派每個基金單位約人民幣0.0371元，約等於0.0405港元。按年計算的分派收益率為8.52%。- 於2024年6月30日，物業整體出租率為84.0%，維持去年同期水準。廣州國金中心：- 廣州國金中心綜合體錄得經營收入為人民幣5.04億元，佔基金收入48.8%。- 廣州國金中心寫字樓成功續約多家重要客戶，續約率高達88.2%。- 「國金天地」上半年商場客流量同比增長5%。- 四季酒店國際客源比例大幅提升，雅詩閣公寓實現整體營收再創歷史新高。廣州越秀金融大廈：- 越秀金融大廈錄得經營收入約人民幣1.82億元，佔基金收入17.6%，出租率達82.9%。- 上半年成功穩定重點優質租戶的續租，空置單元改造去化率高達86%，租戶結構持續向好。積極管理融資風險，有效減低融資成本- 針對年內到期債務，管理人提前籌劃，於2月引入人民幣5.3億元境外循環貸款，固定利率3.70%，於5月引入11.2億港元境內銀行離岸貸款，置換今年到期融資，確保流動性風險得到有效管控。- 管理人把握人民幣融資成本利差窗口，陸續以人民幣貸款置換存量境外外幣融資。截至2024年6月末，已累計引入73.8億人民幣融資並用於置換港元融資，平均成本率為4.55%，同比下降35個基點。- 管理人持續通過融資結構調整，適時增加低成本人民幣融資佔比的方式。2024年6月末房產基金人民幣融資約84.04億元，佔總體融資上升至41%。越秀房產基金主席兼行政總裁及執行董事林德良先生表示：「2024年上半年國內經濟增量主要靠供給側拉動，整體有效需求不足。管理人重點聚焦寫字樓、零售商業及酒店公寓三個核心業態，從市場趨勢中挖需求找機會，從自身問題剖析中找方向求突破，在激烈市場競爭中推行有效之租賃策略及經營措施，務求為基金持有人交出合格答卷。」國金中心國金中心上半年頂住寫字樓市場下行壓力，成功續約「英國領事館」、「蘇黎世財險」、「融捷集團」、「CBD管委會」等重要客戶，續約率高達88.2%，有效穩定優質客戶資源。持續優化租戶結構，引進「策略律所」、「申港證券」、「中原環保」等多家名企，並促成樓內實力客戶「冠領律所」擴租1,071平方米。為引入大面積優質客戶，國金中心主動推進單元整合，提升高區去化效率，目前全層單元已儲備約1萬平方米客戶進入商務談判階段。「國金天地」積極調整經營品類，主動汰換低坪效商戶，優化項目餐飲組合。上半年引進珠江新城首店新奇烘焙品牌「酵社」、廣州首家直營「Subway」形象店、高端商務連鎖咖啡品牌「M Stand」及潮牌零食零售「CURIOUS SNACKS」，商場品牌豐富度和關注度持續拉升。推廣方面，籍「國金天地」開業八周年之際，推出「粵語音樂節&微醺市集&搖擺舞會」營銷活動，擴大宣傳聲量和觸達率。上半年商場客流量同比增長5%。四季酒店在本地奢華市場繼續保持領先地位，連續九年榮獲「福布斯旅遊指南五星級酒店」殊榮。上半年平均入住率為79.0%，酒店國際客源比例大幅提升，有效補充國內市場需求下滑的缺口；平均房價為人民幣2,214元，同比增長0.5%。雅詩閣公寓發揮其大戶型在短住市場的差異化產品競爭優勢，實現整體營收突破天花板，再創歷史新高。上半年平均入住率為90.5%，同比增長0.2個百分點；平均房價為人民幣1,134元，同比增長3.0%。公寓RevPAR競爭指數達146.3，在競爭市場中保持高位，繼續領跑第一梯隊。越秀金融大廈越秀金融大廈上半年共完成7,454平方米續租合同，穩定「光大證券」、「國元證券」、「中期期貨」及「五礦地產」等重點優質租戶的續租，並採取調整樓層、縮減面積等措施，成功挽留三家到期不續客戶在項目內調整。空置單元改造去化率高達86%，引進大型律所品牌「數科律所」及兩家知名優質金融機構，租戶結構持續向好。白馬大廈白馬大廈對標競品市場優質品牌，加強客戶挖掘及儲備，重點解決風險樓層及區域的經營及優化問題，實現招商穩商雙輪驅動，上半年平均出租率95.7%，保持高位運行。上半年白馬創新營銷策略，繼續聯動政府及行業資源，打造品牌影響力系列工程。組團參加上海服博會CHIC，舉辦白馬無限形態二〇二四秋冬聯合訂貨會，白馬品牌在國內外的傳播覆蓋持續增強。財富廣場、城建大廈財富廣場租戶結構進一步優化，引入行業頭部企業「中順潔柔」，首層街鋪無縫銜接進駐「可俊」港式茶餐廳。城建大廈迎來一家政府體育服務機構，去化樓內空置面積約2,500平方米，拉動出租率同比提升5.8個百分點，同時順利續約「柯尼卡美能達」、「大信會計師事務所」等重要客戶，上半年錄得87.9%的較高續約率。維多利廣場維多利廣場實現上半年新簽面積1,033平方米，突破困難單元招商，引入實力美容品牌進駐。積極爭取外部資源投放，配合主力客戶產品上新及活動鋪排節奏，助力「優衣庫」經營業績。通過聚焦上半年節日消費特性，刺激顧客到店消費，上半年客流量同比提升14%。上海越秀大廈上海越秀大廈上半年新簽面積3,400平方米，引入「長安福特」、「太平保險」等知名企業，順利續租「理資堂」、「蘇爾壽」等優質客戶。針對竹園地區有效租賃需求不足，訪客量較少的問題，主動拓展招商渠道，同時優化改善產品，選取重點單元投入帶精裝或傢俱、遺留裝修單元投入翻新，提升來訪量和中盤率。武漢物業越秀財富中心上半年共完成新簽面積1.7萬平方米，並順利續租「瀘州老窖」、「中英人壽」、「廣東廣信」等優質客戶。面對武漢市場淨吸納量低迷、空置率持續高企之困局，越秀財富中心適時檢視租賃政策定價，調整佣金政策及主動拓展管道，重點挖掘同區域內的優質客戶，提升五大行渠道對項目的帶看量，同時加強風險管控。星匯維港購物中心持續優化業態組合，上半年簽約「小米」、「隱星空」及「新東方」等品牌，增加培訓教育和零售類面積佔比，通過持續優化業態組合，活躍整體零售氛圍。上半年商場客流量同比增長37.6%，銷售額同比增加16.2%。杭州維多利杭州維多利有效化解大面積退租風險，上半年完成兩個整層客戶招商新簽，合同有效租金對比上手分別增加20%和12%。續租管理方面，則完成樓內優質客戶「山西路橋」、「中國銀行」及「益起玩」等續簽，保證現有優質客戶穩定經營。未來展望2024年下半年，管理人預計投入資金三千八百多萬元人民幣，積極推進資產增值工程，實現物業保值增值。融資方面，管理人採取一系列流動性管理措施，將年利率控制在合理水平，並關注匯兌風險。鑒於利率繼續維持高位，再融資策略仍將聚焦以低成本境內人民幣融資置換外幣融資為主。同時，管理人將採取穩健的財務政策，以滿足越秀房產基金的營運需要及分派。– 完 –關於越秀房地產投資信託基金越秀房地產投資信託基金（「越秀房產基金」）於2005年12月21日在香港聯交所上市，為全球首只投資於中國內地物業的上市房地產投資信託基金。越秀房產基金目前持有的物業組合包括位於廣州的廣州國際金融中心、白馬大廈、財富廣場、城建大廈、維多利廣場、越秀金融大廈、位於上海的越秀大廈、位於武漢的武漢物業（包括武漢越秀財富中心和星匯維港購物中心）、位於杭州的維多利商務中心以及位於香港的越秀大廈共10項高素質物業，物業產權面積共約118.4萬平方米，分別位於中國廣州市、上海市、武漢市、杭州市及香港市的核心商業區域。物業類型包括甲級寫字樓、商業綜合體、零售商業、酒店、服務式公寓、服裝專業市場等。傳媒查詢:縱橫財經公關顧問有限公司李惠兒 電話: +852 2864 4834梁家儀 電話: +852 2114 4172楊麗明 電話: +852 2864 4833電郵：sprg_yx@sprg.com.hk網址: http://www.sprg.com.hk Copyright 2024 亞太商訊 via SeaPRwire.com.

16 8 月, 2024

第四範式發佈2024年中期業績

財務摘要︰- 2024年上半年總收入人民幣18.67億元，同比增長27.1% - 先知AI平台業務收入為人民幣 12.51億元，同比增長65.4%，占總收入的比例升至67.0% - SHIFT智能解決方案業務收入為人民幣4.53億元，占總收入的24.3% - 式說AIGS服務業務收入為人民幣1.63億元，占總收入的8.7%- 2024年上半年毛利為人民幣7.90億元，同比增長12.1%，毛利率為42.3%- 2024年上半年研發投入超人民幣8.50億元，研發費用率超45.5%- 2024年上半年經調淨虧損額同比收窄4.0%，經調淨虧損率同比收窄至9.0%營運摘要：- 2024年上半年，總用戶數185個，標杆用戶數86個，覆蓋14個行業，標杆用戶群體平均營收貢獻為人民幣1,148萬元，同比增長26.9%。- 先知AI平台：報告期內，發佈了「第四範式先知AI平台5.0」，定位行業大模型開發及管理平台，以提升企業核心競爭力為目標；通過「先知 Inside 模式」，將先知AI平台內的核心技術，作為引擎，結合不同行業的多場景需求，打造智能化產品或解決方案；基於「先知AI平台」的核心能力，攜手「範生態」夥伴，高效打造超30款人工智能產品，截至2024年8月1日，已覆蓋超20個行業的研產供銷服等各類場景。- SHIFT智能解決方案：目前，已推出了搜廣推一體化平台「天樞」、大模型納管平台Model Hub、資料查詢、智能問數、軟件操作助手（Copilot）等應用產品。- 式說AIGS服務：報告期內，持續迭代和優化產品功能，更加注重為開發者提供高效、便捷的操作習慣及程式設計體驗。在功能層面，產品進一步優化沉浸式編碼體驗，開發者無需離開開發環境，直接查詢所需業務、技術文檔，並提高代碼編寫的效率和品質香港, 2024年8月16日 - (亞太商訊 via SeaPRwire.com) – 領先的企業級人工智能軟件公司——北京第四範式人工智能技術股份有限公司（「第四範式」或「公司」，股份代號：6682.HK），公佈截至2024年6月30日止六個月（「報告期內」）的綜合業績。2024年上半年，第四範式營收穩健增長，盈利節奏清晰，總收入人民幣18.67億元，同比增長27.1%。毛利潤人民幣7.90億元，同比增長12.1%，毛利率為42.3%。在保證高研發投入的基礎上，繼續保持清晰減虧趨勢，上半年研發投入人民幣8.50億元，研發費用率45.5%；經調淨虧損額同比收窄4.0%，經調淨虧損率同比收窄至9.0%。2024年上半年，第四範式堅持推動客戶群體多元化，持續鞏固在交通運輸、能源電力、金融、運營商等重點行業的領先地位，報告期內已覆蓋14大行業，總用戶數185個，標杆用戶數86個，標杆用戶平均收入為人民幣1,148萬元 ，同比增長26.9%。報告期內，第四範式核心業務「第四範式先知AI平台」繼續保持強增長態勢，該業務收入人民幣12.51億，同比增長65.4%，占總收入比已達 67.0%。該業務上半年規模化應用與產品生態力拓展並重，已支撐第四範式行業大模型在14個行業規模化應用；同時該業務通過人工智能技術產品化的方式，為各行業產出超30款人工智能產品，未來也將繼續通過產品矩陣，打造AI產品生態，推進業務增長。行業大模型+先知AI產品生態雙引擎 驅動核心業務持續暴漲65.4%先知Inside產品矩陣：用高品質人工智能產品力，拓展第四範式生態2024年上半年，第四範式創新式的通過「人工智能技術產品化」的方式，圍繞核心業務先知AI平台能力，以「先知Inside」模式為引擎推出多維度、多層次的人工智能產品，拓展人工智能應用邊界，構建第四範式產業生態。通過「先知 Inside 模式」，先知AI平台內的核心技術，第四範式可以結合不同行業的多場景需求，打造智能化產品或解決方案。第四範式將先知AI平台的人工智能基礎能力，進行產品化輸出，構建出可應用不同場景的人工智能產品矩陣，用以人工智能產品為核心的「範生態」，帮助生態合作夥伴及其產品實現服務質效雙增長，拓展人工智能技術賦能千行萬業的形態。上半年，公司基於先知AI平台核心能力，攜手「範生態」夥伴，高效打造超30款人工智能產品，截至2024年8月1日，已覆蓋超20個行業的研產供銷服等各類場景。涉及大模型語音合成、物理模擬、多模態生成、AutoML視覺檢測、搜廣推等人工智能技術領域。AI數字人視頻合成平台、vGPU資源池化、5G視頻營銷、AI質檢系統、三維掃描建模設備等多款人工智能產品已在企業中形成多場景應用。行業大模型：規模化能力凸顯 已落地14大行業發展10年來，第四範式先知AI平台完成了從1.0版本到先知AI平台5.0版本的迭代。今年最新發佈的「第四範式先知AI平台5.0」定位為行業大模型開發及管理平台。平台以提升企業核心競爭力為目標，在支援接入企業各類模態資料的基礎上，提供大模型訓練、精調等低門檻建模工具、科學家創新服務體系、北極星策略管理平台、大模型納管平台、主流算力適配優化等能力，實現端到端的行業大模型的構建、部署、管理服務。報告期內，基於「第四範式先知AI平台 5.0」能力，第四範式與標杆使用者及合作夥伴，規模化打造了學術翻譯、健康管理、水電管理、水利、3D輔助設計、供應鏈、流體動力等諸多領域行業大模型，覆蓋交通運輸、資料中心、金融、能源電力、運營商、資訊技術、智能製造、零售等14大行業，高效賦能企業多場景、高價值數字化轉型，穩步推進人工智能技術在千行百業的規模化應用。未來，隨著先知AI平台能力的持續提升，第四範式將持續深入探索行業大模型在企業服務領域的高價值應用場景，通過規模化應用與產品生態力的拓展，加速推進人工智能產業落地進程。在戰略展望方面，第四範式董事會主席、執行董事、首席執行官兼總經理戴文淵博士表示：「第四範式創立近10年，秉承創新驅動發展，致力於用『第四範式』技術理論，賦能千行萬業，為人工智能技術的發展貢獻力量。報告期內，我們致力於用創新驅動人工智能技術多元應用，將人工智能技術產品化輸出，上半年為各行業高效打造30多款人工智能產品，我們基於先知AI平台的核心能力，攜手『範生態』夥伴，截至2024年8月1日，已覆蓋超20個行業的研產供銷服等各類場景，用高品質產品構建人工智能產業生態。未來，我們將繼續以技術創新為支撐，輸出高品質產品矩陣，打造AI產品生態，在推進業務增長的同時，多元化提升千行萬業的人工智能應用效率與核心競爭力。」 Copyright 2024 亞太商訊 via SeaPRwire.com.

16 8 月, 2024

Genes Tech Group Announces 2024 Interim Results

HONG KONG, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Genes Tech Group Holdings Co. Ltd (“Genes Tech Group” or “The Group”; Stock Code: 8257.HK) announces its interim results for the six months ended 30 June, 2024 (“the period”). During the period, the Group recorded the total revenue of approximately NTD535.01 million, Total comprehensive income for the period attributable to owners of the Company amounted to approximately NTD31.30 million. Basic earnings per share were NTD3.87 cents.During the period, revenue from turnkey solutions amounted to approximately NTD226.60 million, accounting for approximately 42.35% of the Group’s total revenue. The revenue from trading of parts and used SME amounted to approximately NTD308.41 million, accounting for approximately 57.65% of the Group’s total revenue. During the period under review, under the ongoing geopolitical tensions, the Group deepened cooperation with existing international clients and continually explored new areas and models of collaboration. The Group's revenue from operation in Japan significantly increased by 7,038.01% compared with last year, representing approximately 9.79% of the Group's total revenue, while revenue from operation in the United States increased by 15.54% from last year, representing approximately 23.70% of the Group's total revenue.In the first half of 2024, the rise of generative artificial intelligence (AI) technology has provided significant growth impetus for demand on chips and memory. However, the uncertainties of the global economic environment, along with the slowdown in the growth of the industrial and automotive sectors, leading to a slower-than-expected pace of recovery for the entire semiconductor industry. According to the data recently released by the Semiconductor Industry Association (SIA), the monthly sales of the global semiconductor industry have achieved year-on-year growth since 2024. In May, sales reached USD49.1 billion, with an annual growth rate of 19.3% and a monthly growth rate of 4.1%. Such annual growth rate was the highest since April 2022, showcasing the vigorous development trend of generative AI applications, which brought a strong growth momentum to the semiconductor industry.Mr. Yang Ming-Hsiang, Chairman and Chief Executive Officer concluded: “With the rapid development of AI technology, the market is entering a new era fully empowered by AI. This transformation not only deeply reconstructs industry ecosystems but also opens unprecedented golden opportunities for the semiconductor industry. The robust demand for AI and high-performance computing data centers is driving chip manufacturers to establish closer collaborations with memory, packaging and testing companies, working together to build a strong ecosystem, thus enhancing the overall competitiveness of the entire industry chain. However, the complex geopolitical landscape continues to have profound effects on the global semiconductor industry, especially in AI, which is a core area of Sino-US competition. The Group will adopt a cautious strategy, flexibly adapting to market changes and seizing development opportunities. At the same time, the Group will also strive to achieve breakthroughs in key technologies to solidify our market position in intense competition, aiming to create long-term and sustainable value returns for the shareholders.”About Genes Tech Group Holdings Co Ltd (Stock Code: 8257.HK)Genes Tech Group Holdings Co. Ltd is a turnkey solution provider and exporter of parts and used SME in Taiwan. Since the commencement of its business in 2009, the Group mainly engaged in providing turnkey solution for parts and used SME for its customers and modifying and/or upgrading the semiconductor equipment of its production systems according to customers needs. In addition, the Group is also engaged in the trading of SEM and parts. The SME and parts supplied by the Group included furnaces, clean tracks and other related items, which were used at the front-end of the semiconductor manufacturing process, wafer fabrication such as deposition, photoresist coating and development, and these were extensively applied in mobile phones, game consoles, DVD players, automotive sensors and other digital electronic products. Visit https://www.genestech.com/en/.Press release distributed by Vitalink Consultants for Genes Tech Group Holdings Co. Ltd. For enquiries, please contact:Ms. Natural Lau T: +852 2529 7999 E: Natural.lau@vitalink.com.hk Copyright 2024 ACN Newswire via SeaPRwire.com.

15 8 月, 2024

日清食品為MSCI全球微型股指數（MSCI香港指數）成份股之一

香港, 2024年8月14日 - (亞太商訊 via SeaPRwire.com) – 日清食品有限公司（「日清食品」或「公司」，連同其附屬公司統稱「集團」；股份代號：1475）欣然宣布集團已獲納入MSCI全球微型股指數（MSCI香港微型股指數），將於2024年8月30日（星期五）生效。日清食品執行董事、董事長兼首席執行官安藤清隆先生表示：「我們相信，集團被納入MSCI香港微型股指數，體現了資本市場對我們業務策略和營運卓越的認可。我們預計，是次發展將吸引更多投資者對集團的增長潛力產生興趣，並有機會帶來更廣泛的股東基礎。展望未來，我們會積極豐富產品組合，並持續為股東提供更大價值。」MSCI全球微型股指數涵蓋了23個已開發市場國家的微型市值代表性。該指數包括6,406個成分股，大致涵蓋了每個國家約1%的自由流通市值。該指數的評估乃基於多個關鍵因素，包括最低市值、自由流通股及流動性、外國投資者持股比例要求，以及最短交易時間要求。有關日清食品有限公司日清食品有限公司（「日清食品」，連同其附屬公司統稱「集團」；股份代號：1475）為一間在中國內地及香港知名的食品公司，主要專營優質即食麵市場，旗下眾多品牌不僅知名度高，且廣受顧客喜愛。集團於1984年正式於香港設立營業據點並為香港最大的即食麵公司。集團主要生產及銷售兩個核心企業品牌「日清」及「公仔」，以及多元化的家庭食品品牌組合，出品具標誌性和優質的即食麵、優質冷凍食品（包括冷凍點心及冷凍麵條）並銷售和分銷其他食品及飲料產品（包括蒸煮袋裝產品、零食、礦泉水、醬料及蔬菜產品）。集團五個旗艦品牌「合味道」、「出前一丁」、「公仔麵」、「公仔點心」及「福」在香港亦是其各自食品類別中最受歡迎的選擇。中國內地市場方面，集團以創新技術推出「ECO杯」概念，銷售活動主要集中在中國內地的一線及二線城市。日清食品被納入五項恒生指數，包括恒生綜合指數、恒生綜合小型股指數、恒生綜合行業指數-必需性消費、恒生港股通消費行業指數和恒生港股通必需性消費指數。日清食品現可通過滬港通及深港通下港股通進行交易。詳情請瀏覽 www.nissingroup.com.hk。 Copyright 2024 亞太商訊 via SeaPRwire.com.

15 8 月, 2024

AsiaMedic continues growth streak with 23% increase in revenue for First Half ended 30 June 2024

SINGAPORE, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - SGX Catalist-listed AsiaMedic Limited (the “Company” and together with its subsidiaries, the “Group”) announced its financial results for the financial period ended 30 June 2024 (“1H2024”).The Group’s 1H2024 revenue increased by S$2.4 million or 23% from S$10.7 million for 1H2023 to S$13.2 million due to the increase in revenue from the imaging and aesthetic businesses. The increase follows three consecutive years of revenue growth as the Group continues to pursue further capacity expansion to serve more patients.The increase in revenue from the diagnostic imaging business was primarily due to the addition of a third MRI scanner in the last quarter of 2023 while the increase in revenue from the aesthetics business was due to the engagement of a senior aesthetic doctor and the acquisition of the medical aesthetics business of LE Private Clinic in August 2023.The set-up of the new diagnostic imaging centre in Novena as well as expanded operations at Shaw Centre have necessitated the hiring of additional staff and doctors amidst intense competition for talent in the industry. The additional manpower was also supported by the purchase of new equipment incorporating the latest technology.The Group’s consumables expenses increased by 44% to S$1.0 million, personnel expenses increased by 30% to S$7.3 million, and laboratory and consultancy fees increased by 55% to S$2.2 million. In addition, depreciation of right-of-use assets increased by 36% to S$0.7 million for 1H2024 due to the purchase of the new MRI scanner in the last quarter of 2023 and the new CT scanner in 1H2024, as well as the lease of new clinic space at Orchard Building in 1H2023.As a result, the Group recorded a borderline loss of S$0.1 million for 1H2024 as compared to a profit of S$0.6 million for 1H2023. On the balance sheet, the Net Asset Value per share (cents) fell slightly by 0.04 cent from 1.18 cents per share to 1.14 cents per share.Investing for Future GrowthMr Arifin Kwek, Chief Executive Officer of AsiaMedic Limited, said, “We are encouraged by the continued revenue growth which reflects our ongoing pursuit of further capacity expansion to serve more patients. The Group’s new diagnostic imaging centre set-up in partnership with Sunway Berhad remains on track to commence operations by November 2024 and will nearly double the Group’s diagnostic imaging capacity.”“While our initial essential investments in new talent and technology may lead to margin compression in the short term, the expanded capacity and increase in productivity will also generate economies of scale and operational efficiencies which will play a significant role in the Group’s focus on attaining sustainable higher margins in the longer term,” he added.In August 2024, the Group implemented a new artificial intelligence virtual assistant to automate the scheduling of patient appointments. The system will free clinic staff from mundane tasks, allowing them to dedicate more time for high value in-person patient care.The Group’s focus on talent acquisition and investing in technology will pave the way for long-term sustainable growth and the creation of shareholder value.This press release should be read in conjunction with the financial statements announcement for 1H2024 uploaded on SGXNet.For media and analysts’ queries, please contact:Waterbrooks ConsultantsWayne KooT: (65) 9338 8166E: wayne.koo@waterbrooks.com.sgAbout AsiaMedic LimitedAsiaMedic Limited together with its subsidiaries (“AsiaMedic” or the “Group”) is a leading healthcare provider in Singapore which provides holistic solutions through integrated application of the latest medical technologies to prevent and detect early illnesses to achieve positive experiences and clinical outcomes for patients.The Group is committed to helping clients through practical and personalised solutions delivered with the highest professional standards of service and expertise in a timely, safe and consistent manner. Conveniently located at Orchard Road, AsiaMedic is a preferred one-stop centre for:Diagnostic imaging and radiology servicesMedical wellness and health screening servicesPrimary healthcare servicesMedical aesthetic services and productsFor more information, please visit www.asiamedic.com.sgThis announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd. It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Pauline Sim (Registered Professional) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 6319 4954. Copyright 2024 ACN Newswire via SeaPRwire.com.

15 8 月, 2024

Kincora Participation in the Sharewise Webinar

Melbourne, Australia--(ACN Newswire via SeaPRwire.com - August 14, 2024) - Kincora Copper Limited (ASX: KCC) (TSXV: KCC) (Kincora or the Company) is pleased to be participating in the Sharewise Webinar to be held today, Thursday August 15th, from 1:30pm Australian Eastern Standard Time (AEST).President & CEO Sam Spring will provide investors and shareholders an update on Kincora's asset portfolio, partner and corporate strategy outlining recent milestones, upcoming catalysts and with the opportunity for Q&A. A copy of the presentation is available at: https://images.newsfilecorp.com/files/2305/220005_664006_kincora_copper_participation_in_the_sharewise_webinar.pdfThis webinar can be viewed live via Zoom. Registration is free and available at:https://zoom.us/webinar/register/1917231614965/WN_3nN-VZ0lRpucefIyqLI2AAA recorded copy of the webinar will be made available following the event on Kincora's website (https://kincoracopper.com/interviews/ ) and Sharewise's YouTube (https://www.youtube.com/@sharewiseau ).This announcement has been authorised for release by the Board of Kincora Copper Limited (ARBN 645 457 763)About Kincora Copper LimitedKincora is dual listed on the ASX and TSX-V (ticker "KCC") and is an active explorer and project generator focused on world-class copper-gold discoveries. The company recently executed four agreements that unlock up to A$60 million in multiple year partner funding. Further new projects that offer a clear value path and targeted partnerships are proposed.Kincora's portfolio includes district scale landholdings and scalable drill-ready targets in both Australia and Mongolia's leading porphyry belts, the Macquarie Arc and Southern Gobi, respectively, and, the Company is targeting initial exposure to 10,000m of drilling in the next 6-month before ramping up to over 30,000 metres pa of drilling.For more information please visit Kincora's website at www.kincoracopper.com.For further information please contact: Sam Spring, President and Chief Executive Officersam.spring@kincoracopper.com or +61431 329 345Executive office400 - 837 West Hastings StreetVancouver, BC V6C 3N6, CanadaTel: 1.604.283.1722Fax: 1.888.241.5996Subsidiary office Australia Vista AustraliaLevel 4, 100 Albert RoadSouth Melbourne, Victoria 3205To view the source version of this press release, please visit https://www.newsfilecorp.com/release/220005 Copyright 2024 ACN Newswire via SeaPRwire.com.

15 8 月, 2024

Egyptian Heritage and Palestinian Folklore Shine at Alamein Festival

Egyptian Folk Traditions Take Centre Stage at AlameinIconic Performances Celebrate Egyptian and Palestinian HeritageOpera Al Layla Al-Kabira and Reda Troupe Steal the ShowAL ALAMEIN CITY, EGYPT, Aug 15, 2024 - (ACN Newswire via SeaPRwire.com) - The second edition of Alamein Festival 2024 celebrated Egypt's diverse cultural identity, heritage, and folk traditions.Part of the iconic performances throughout the festivalThe festival, organized by the United Media Services (UMS) under the patronage of Dr. Ahmed Hano, the Egyptian Minister of Culture, featured performances from folkloric groups across Egypt, highlighting the country's rich artistic and musical diversity.The Arab Opera troupe, led by Mohamed Mostafa, presented performances based on famous Egyptian songs, plays, and films, reinterpreted with new musical arrangements, along with a segment for children featuring beloved songs.The Ismailia troupe paid tribute to the Suez Canal region's folklore with performances like "The Saayaden" and "Betghani l meen ya hamam," underscoring Ismailia's cultural richness and significant contribution to the festival's diversity.Key performances included those by the "El-Horria" or Freedom and Aswan Folk Arts teams. The Aswan team, led by Medhat Mahram, performed Nubian folkloric pieces such as "Al-Arajeed" and "Al-Najrashad," with musical interludes by artists Hamada Harby and Omar Mustafa. With its rich historical and cultural significance, Aswan was a prominent and fitting feature of the festival.The Freedom team, under Nasreldin Mohamed, performed distinct pieces from Alexandria, including the "Banat Bahry" dance and the "Alexandrian Wedding Procession." These performances vividly brought Alexandria's rich cultural heritage to life.Additionally, the Assiut City Folk Arts team showcased traditional performances from the Assiut governorate, including "Al-'Asaayah," "Al-Tahmilah," and the "Arouset El-Mawlid" dance. These performances reflected Assiut's diverse historical influences, encompassing the Pharaonic, Roman, Coptic, and Islamic periods.A standout moment of the festival was the presentation of "Opera Al Layla Al-Kabira," a piece celebrating Egyptian visual identity by depicting Mawlid festivities. This operetta, composed by the late Salah Jahin with music by Sayed Mekkawy, remains a cultural cornerstone of Egyptian heritage.The iconic Reda Troupe also took part, performing a vibrant array of Egyptian folkloric dances. Their performance added to the celebration of the diverse heritage of various governorates, including "Dhaheya," and "Al-Hejala,"Palestinian folklore was also celebrated, with a concert featuring singer Mohamed Mounir and Dina El-Wedidi. El-Wedidi performed the operetta "Ragieen" and the iconic song "Leve Palestina," accompanied by a Palestinian dance troupe that showcased traditional performances in Palestinian costumes. This segment was a powerful celebration of the shared cultural heritage between Egypt and Palestine, making the festival a symbol of regional cultural unity.The 2024 edition of the New Alamein Festival featured a variety of activities, including theatrical performances produced by renowned producers and starring famous stars and young artists, football matches featuring legends and star players, visits from Egyptian ministers, the launch of major investment initiatives and partnerships, and collaboration with the United Media Services, the founder and organizer of Alamein Festival.For more information, please visit the festival website: https://elalameinfestival.comContact InformationEman Salempress@30n.orgSOURCE: Alamein Festival Copyright 2024 ACN Newswire via SeaPRwire.com.

15 8 月, 2024

Solar District Cooling Group Berhad Signs Underwriting Agreement with Mercury Securities Sdn Bhd for Its IPO on the ACE Market of Bursa Malaysia Securities Berhad

KUALA LUMPUR, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Solar District Cooling Group Berhad ("SDCG") is pleased to announce that it has entered into an underwriting agreement with Mercury Securities Sdn Bhd (“Mercury Securities”) today for its upcoming initial public offering ("IPO") on the ACE Market of Bursa Malaysia Securities Berhad.1.Mr Chris Lai Ther Wei, Director, Head of Capital Markets, Mercury Securities 2.Ms Tan Tai Kim, Director, Corporate Finance, Mercury Securities 3.Mr Chew Sing Guan, Managing Director of Mercury Securities 4.Mr Edison Kong, Managing Director, Solar District Cooling Group 5.Ms Eileen Liuk, Executive Director, Solar District Cooling Group 6. Ms Sheryn Chow Suet Yim, Director, Corporate Finance, Mercury Securities [L-R]SDCG and its subsidiaries (“Group”) are principally involved in the provision and maintenance of building management systems (BMS), solar thermal solutions and energy saving services. The Group has a proven track record of enhancing energy efficiency across various sectors and strives to establish benchmarks in energy management and cost efficiency.The IPO involves the public issue of 118,670,000 new ordinary shares ("Issue Shares"), representing 28.00% of SDCG’s enlarged issued share capital of 423,822,460 ordinary shares upon its listing.The Issue Shares will be allocated in the following manner:Malaysian Public: 21,192,000 Issue Shares representing 5.00% of the enlarged issued share capital for application by the Malaysian public, with 50.00% set aside for Bumiputera investors.Eligible Persons: 21,192,000 Issue Shares representing 5.00% of the enlarged issued share capital for application by eligible directors, employees, and persons who have contributed to the Group’s success.Selected Investors: 76,286,000 Issue Shares representing 18.00% of the enlarged issued share capital made available by way of private placement to selected investors.Mercury Securities will underwrite all the 42,384,000 Issue Shares made available for application by the Malaysian public and eligible persons.Mr. Edison Kong, Managing Director of SDCG, expressed his enthusiasm for the IPO, stating, “Our listing will enhance our visibility and reputation in the market and enable our directors, employees, business partners, and public investors to participate in the growth and continued expansion of our business, increasing shareholder value. We would like to express our sincere gratitude to Mercury Securities for their support and confidence in our Group."He added, "This corporate milestone will help scale our Group to new heights by tapping new opportunities and responding to the evolving needs of our customers and market trends. We remain focused on providing innovative solutions that create value for our customers, striving to exceed their expectations.Mr. Chew Sing Guan, Managing Director of Mercury Securities said, "We are delighted to be the Principal Adviser, Sponsor, Sole Underwriter, and Sole Placement Agent for SDCG and to play a part in their new corporate journey as a listed company on the ACE Market of Bursa Malaysia Securities Berhad. The listing will enable SDCG to tap into the capital market for its growth and expansion plans in the future."1. Mr Chew Sing Guan, Managing Director of Mercury Securities 2. Mr Edison Kong, Managing Director, Solar District Cooling Group[L-R]ABOUT SOLAR DISTRICT COOLING GROUP BERHADSolar District Cooling Group Berhad (SDCG) and its subsidiaries (the “Group”) is an established services provider of energy-efficient building management and solar thermal systems in Malaysia. The Group specialises in the design, installation, and maintenance of BMS and solar thermal solutions, serving a diverse range of sectors including commercial, institutional, and industrial properties. With a commitment to sustainability and innovation, SDCG has earned a reputation for excellence in the building management system and solar thermal industries.For more information, visit www.sdc.myIssued By: Swan Consultancy Sdn Bhd on behalf of Solar District Cooling Group.For more information, please contact:Jazmin WanTel: +60 17-289 4110Email: j.wan@swanconsultancy.bizWilliam YeoTel: +60 16-213 2103Email: w.yeo@swanconsultancy.biz Copyright 2024 ACN Newswire via SeaPRwire.com.

15 8 月, 2024

新能源助推綠色轉型 中國港能打造智慧能源新藍圖

香港, 2024年8月14日 - (亞太商訊 via SeaPRwire.com) – 中國港能智慧能源集團有限公司（股份代號：0931.HK，以下簡稱「中國港能」）在香港成功召開2024年度業績投資者交流會。本次活動是自中國港能戰略轉型後首次面向全球投資者舉辦的線下交流會，不僅是中國港能在全球能源版圖中邁出堅實步伐的重要里程碑，更是一次面向未來、共謀綠色發展的深度對話。出席本次會議的有，中國港能董事會主席簡志堅，執行董事、總裁鄧耀波，副總裁劉永濤，陳雷昕，高級財務總監藍海。活動過程中，中國港能管理層就公司概况、財務表現及未來展望等內容與多家知名投資機構的投資者、分析師進行詳細介紹，並就行業發展和前景展開了深入交流，進一步加深資本市場對公司發展和前景的全面認知。新管理團隊加盟領航，業務轉型成效斐然為快速落實新的公司戰略，中國港能于2023年10月引進了一支擁有豐富管理經驗和市場洞察力的精英管理團隊，新的管理成員長期深耕于能源領域，具備成熟的行業管理經驗，能够穩定地駕馭複雜多變的行業環境。在過去的一年裡，公司原有天然氣存量業務穩步發展，同時在新的管理團隊帶領下，中國港能成功開拓了新能源業務，助推公司綠色能源戰略轉型，為公司長遠發展注入了新活力。財務指標增長强勢，多元化戰略未來可期截至2024年3月31日的財政年度內，在全新管理團隊的引領下，公司經營穩步發展，整體經營業績實現了令人矚目的114%年度同比增幅，毛利也取得了494%的大幅增長，彰顯出驚人的增長動能。在具體方面，中國港能原有天然氣業務持續穩健前行，相較去年同期實現了大幅增長，穩固了公司的業務基礎。同時公司在新能源領域取得了從零到一的飛躍性突破，構建起多元並進的收入增長格局。下半年度中國港能新佈局的新能源業務在短短四個月便迅速展現出强勁的市場適應性和盈利能力，進一步彰顯了公司在新能源領域的深厚潜力與市場競爭力。新能源+天然氣雙輪驅動，開啓智慧能源新篇章綠色能源轉型是歷史發展的必然趨勢，清潔能源市場前景充滿巨大想像空間，在新能源時代機遇之下，中國港能作為根植于傳統能源領域的企業，將緊緊抓住國家能源結構優化的政策機遇，持續緊跟市場趨勢，在保證天然氣業務基本盤穩定的前提下强化新能源業務拓展，在能源轉型歷程中實現社會與企業的雙贏。中國港能不僅將在能源轉型、管理升級上持續積極創新，同時也將繼續佈局人工智能、雙碳戰略、數字資產交易平台等新興領域，力求在全球能源舞台上發揮更加積極的作用，為股東持續創造更多價值。未來，中國港能將依托能源運輸和儲存的終端商業優勢，積極與國際夥伴開展合作，拓展業務輻射範圍，開拓上游市場版圖，不斷加强全球市場拓展和滲透，並通過天然氣和新能源業務積累的行業優勢，為可持續發展貢獻力量，為股東和合作夥伴創造長期價值。同時，中國港能也將積極響應國家號召，深入貫徹中共中央、國務院《關于加快經濟社會發展全面綠色轉型的意見》精神，將綠色發展理念融入企業發展戰略的核心，在《意見》明確指出的：構建綠色低碳高質量發展空間格局、加快產業結構綠色低碳轉型、穩妥推進能源綠色低碳轉型、推進交通運輸綠色轉型、推進城鄉建設發展綠色轉型等五大領域貢獻中國港能的智慧與力量，助力經濟社會全面邁向綠色化、低碳化發展。-完-關于中國港能中國港能智慧能源集團有限公司（簡稱「中國港能」），2001年在香港聯交所主板上市，股票代碼00931，主要經營新能源和天然氣業務的投資、建設、運營與技術服務的綜合能源服務商。中國港能致力于提供最優的能源系統方案，整合地熱能、空氣能、生物質能等多種清潔能源，依托自主研發的「IDH 智慧供熱」與「ICE 智慧綜合能源」技術平台，為居民小區、公共建築、工業企業等提供智慧綜合能源服務。公司還佈局了智慧供熱、綜合能效、裝備製造、雙碳等9大能源服務業務，推動現代能源體系建設。在天然氣領域，中國港能深耕產業鏈上下游，與多家油氣行業領軍企業建立長期合作關係，擁有近300台套自有LNG運輸車輛，構建了全國性的銷售網絡和供應鏈物流體系。同時，公司在城市管道燃氣、區域能源站等領域積極佈局，成為各地經濟社會和環保事業發展的重要力量。中國港能服務超過700個終端項目，業務遍及國內外20多個省市及澳大利亞、新西蘭、英國、德國等國家。公司榮獲多項榮譽，包括福佈斯亞洲區頂尖200最具成長型企業獎，並與國際能源署共同舉辦「能源可持續發展國際論壇」，被聯合國選為戰略合作夥伴。 Copyright 2024 亞太商訊 via SeaPRwire.com.

14 8 月, 2024

靖洋集團公佈2024年中期業績

香港, 2024年8月14日 - (亞太商訊 via SeaPRwire.com) – 靖洋集團控股有限公司（「靖洋集團」或「集團」，股份代號：8257.HK）宣佈截至 2024年6月30日止六個月（「期內」）之中期業績。期內，集團總收益約新台幣535.01百萬元。本公司擁有人應佔期間全面收益總額約新台幣31.30百萬元。每股基本盈利為新台幣3.87仙。期內，統包解決方案的收益約新台幣 226.60百萬元，佔集團總收益約42.35%。零件及二手半導體製造設備買賣的收益約新台幣308.41百萬元，佔集團總收益約57.65%。回顧期內，在地緣政治局勢持續緊張的環境下，本集團深化與現有國際客戶的合作關係，而且不斷探索新的合作領域和模式。本集團源自日本業務的收入較去年大幅增加7,038.01%，佔本集團總收益約9.79%，而源自美國業務的收入則較去年增加15.54%，佔本集團總收益約23.70%。在2024年上半年，生成式人工智能（AI）技術的興起為晶片及記憶體需求帶來了顯著的增長動力，然而，全球經濟環境的不確定性、工業和汽車市場的增速放緩等影響，使得整個半導體行業的復甦步伐不如預期。半導體產業協會(SIA)近日發表的數據顯示，2024年來全球半導體產業月度銷售額均實現同比增長。5月銷售額達491億美元，年度增長率高達19.3%，月度增長率也達到4.1%，年度增幅度是自2022年4月以來最大，充分展現生成式AI應用蓬勃發展態勢，為半導體產業帶來強大增長動力。靖洋集團主席兼行政總裁楊名翔先生總結：「隨著AI技術發展迅速，市場正邁入一個由AI全面賦能的新時代，這場變革不僅深度重構產業生態，更為半導體行業開啟了前所未有的黃金機遇。AI與高性能運算資料中心的強勁需求，驅動著晶片製造商與記憶體、封裝測試等企業之間建立起更為緊密的合作關係，攜手構建起一個強大的生態系統，從而增強整個產業鏈的綜合競爭力。然而，地緣政治的複雜態勢持續對全球半導體產業施加深遠影響，特别是AI作為中美科技競爭的核心領域。本集團將採取審慎的策略，靈活應對市場變化，緊抓發展機遇。同時，本集團也將致力於在關鍵技術上實現突破，以鞏固我們在激烈競爭中的市場地位，為股東創造長期、可持續的價值回報。」 關於靖洋集團控股有限公司（股份代號：8257.HK）靖洋集團控股有限公司為一間總部位於台灣的零件及二手半導體製造設備的統包解決方案供應商及出口商。集團自於2009年開始業務以來，主要為客戶提供零件二手半導體製造設備件的統包解決方案，按客戶需要改造及/或升級其生產系統的半導體設備，亦從事半導體製造設備及其零件買賣。集團所提供的半導體製造設備及零件包括熱爐管、顯影裝置等，用於半導體的前端製造過程、晶圓加工，如沉積、光阻塗佈及顯影，更可廣泛應用於手機、遊戲機、DVD播放機，以及車用感應器等數碼電子產品。本新聞稿由滙滔顧問有限公司代表靖洋集團控股有限公司發佈。詳情垂詢：劉育然小姐電話：(852) 2529 7999電郵：Natural.lau@vitalink.com.hk Copyright 2024 亞太商訊 via SeaPRwire.com.

14 8 月, 2024

Kincora and AngloGold Ashanti’s First Drilling Program

The first ever copper-gold focused drilling program at the northern portion of the Nyngan Project will shortly commence with earn-in partner AngloGold Ashanti Australia (AngloGold Ashanti).New district-scale potential with up to eight large intrusive complex targets to be drill-tested for the first time in this initial first phase program.Approximately 6 to 8 drill holes for an estimated 4000-5000 metres budgeted before the summer break. Kincora is managing the program and will receive a 10% management fee. The program is the first by Kincora in partnership with AngloGold Ashanti, which has the right to spend up to A$50 million to earn an 80% interest in the Nyngan and Nevertire Projects.Fleet Space Technologies Pty Ltd's (Fleet Space) ongoing Ambient Noise Tomography (ANT) and gravity geophysical surveys at the Nyngan Project are progressing well and are expected to complement upcoming drilling.Melbourne, Australia--(ACN Newswire via SeaPRwire.com - August 14, 2024) - Kincora Copper Limited (TSXV: KCC) (ASX: KCC), (Kincora or the Company) is pleased to outline plans for the next chapter of copper-gold focused drilling in the Macquarie Arc, Central West New South Wales (NSW) with a first program in partnership with and funded by AngloGold Ashanti to shortly commence at the Nyngan Project.Sam Spring, President and CEO of Kincora, commented: "We are very excited by the potential of the Northern Junee-Narromine belt where we are seeking not to just confirm a new significant porphyry Cu-Au deposit but a new district and series of discoveries. The strategic appeal and value of a new porphyry district has been clearly illustrated in the Vicuña district with corporate activities by BHP and Lundin Mining this month supporting over C$8 billion of value being recognised for a cluster of four new major discoveries. Recent planning and targeting activities with our partner AngloGold Ashanti has significantly expanded the number of targets, the drilling activities needed and planned to test a series of major and previously undrilled interpreted magmatic complex targets at the Nyngan Project. Initially we are aiming to test up to eight new major intrusive system complex targets before year end in this first phase program which focuses on the very compelling northern Nyngan "Ace of Spades" region.Recent neighbouring explorer drilling is also supporting the potential of a series of Macquarie Arc intrusive complexes to the immediate east of the "Ace of Spades" target area along a potentially important common transverse structure providing further encouragement to the potential of a new porphyry district scale opportunity."BackgroundThe undercover extensions of the renowned Macquarie Arc porphyry copper-gold geology are globally significant exploration opportunities offering new district(s) scale discovery potential. The region has attracted four earn-in and joint venture agreements in the last 12 months supporting potentially over $200 million in exploration and development expenditure.The most recent notable example of a new emerging globally significant porphyry district is the Vicuña district in the central Andes in Argentina on the border of Chile, which is largely consolidated by Lundin group entities and BHP and situated at over 4000m altitude 1.Within this district NGEX Resources Inc in 2009 held three early-stage exploration projects and, at the time, had a market capitalisation of approximately C$40 million. These same projects are all still at a pre-development phase but have yielded four large-scale discoveries currently valued at over C$8 billion 2.In comparison, the central west of NSW benefits from multiple world-class mines, existing infrastructure, high-quality publicly available exploration data and an existing mineral endowment of over 160 million gold equivalent ounces 3. Regional geophysics strongly indicates that Kincora's Nyngan license hosts the largest volcano-intrusive complex of the Macquarie Arc, which is almost untested, offering new district scale potential.Kincora, as the early entrant, has secured a district scale position in the interpreted shallow-to-moderate covered core sections of the Northern Junee-Narromine Belt (NJNB) by pegging Nyngan and Nevertire which are now in partnership with AngloGold Ashanti 4.The imminent first-ever drilling program at the northern portion of the Nyngan Project will focus on the "Ace of Spades" region and test a wide range of untested, large intrusive-related Cu-Au targets. The program seeks to confirm the potential for a series of new Macquarie Arc intrusive complexes and provide vectors for follow up drilling - see Figure 1.Subject to permitting, access and weather conditions, the drilling program is anticipated to commence from mid September and will continue until the summer break, comprising up to eight holes for an estimated 4000-5000 metres.Recent planning and targeting activities with our partner AngloGold Ashanti have significantly expanded the number of targets, the drilling necessary to test a series of major and previously-undrilled interpreted magmatic complex targets at the Nyngan Project. This first program will test the potential for up to eight separate large intrusive complex targets.The program will comprise cost-effective mud-rotary drilling through the post mineral cover sequence with diamond core drilling upon refusal and testing of the targeted basement.Kincora is managing the exploration program and will receive a 10% management fee as the program is funded by AngloGold Ashanti via the up to $50 million earn-in and joint venture agreement for the Nyngan and Nevertire Projects.These drill targets include an existing high priority large intrusive complex target, which is currently the focus of Fleet Space's ongoing Ambient Noise Tomography (ANT) and gravity geophysical surveys within the northern portion of the Nyngan Project 5. Figure 1: District-scale series of major and untested magmatic complex targets with in the northern Nyngan "Ace of Spades" region that potentially represent the largest volcano-intrusive complex of the Macquarie Arc. Kincora is managing the exploration program and will receive a 10% management feeTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/2305/219846_kincora.jpgThe geophysical surveys are seeking to map and refine the interpretation of the paleo-surface and basement rocks and refine modeling of the targeted alteration, intrusions and structures.Recent neighbouring exploration drilling by Inflection Resources ("Inflection") is further supporting the potential of a series of Macquarie Arc intrusives to the immediate east of the "Ace of Spades" target area at Nyngan. Inflection has announced encouraging results at the Canonba target situated on the license boundary to the Nyngan Project, and located approximately 5km from its Duck Creek target, which is a Phase 2 designated project with its earn-in and joint venture partner AngloGold Ashanti 6. The Canonba, Duck Creek and Ace of Spades target areas potentially host important common transverse structures providing further encouragement about the potential of a new district-scale porphyry opportunity.About the Nyngan ProjectThe Nyngan license (Exploration Licence 8929) was the first ground Kincora secured in NSW. It is a large 762km2 direct application tenement granted by the NSW State Government covering a significant portion of the interpreted under cover section of the northern Junee-Narromine Belt 7. The Junee-Narromine Belt is one of the two largest belts of the Macquarie Arc, Australia's foremost porphyry belt, which hosts a mineral endowment of over 160 million gold equivalent ounces.The license hosts limited, but encouraging, prior explorer drilling that has been inadequately followed up, with regional geophysics supporting a new potential district-scale setting hosting interpreted, large-scale, intrusive complex targets.In May 2024, Kincora signed a definitive multiple-phase Earn-in and Joint Venture Agreement (Agreement) over the Nyngan and Nevertire licences with a wholly owned subsidiary of AngloGold Ashanti plc (NYSE: AU) (JSE: ANG), the world's fourth largest gold miner by production, which has a successful track record for Greenfields discovery success.AngloGold Ashanti has the right to spend up to A$50 million to earn an 80% interest through:A$25 million of exploration expenditure to earn a 70% joint venture interest (Phase I) including a minimum A$2 million expenditure obligation, with Kincora the initial operator for a 10% management fee. Completion of a Pre-Feasibility Study (PFS) or funding of a further $25 million of expenditure to earn a 80% joint venture interest (Phase II).In July 2024, separate to the Agreement with AngloGold Ashanti, Kincora formed a partnership with Fleet Space Technologies Pty Ltd (Fleet Space) to undertake Ambient Noise Tomography (ANT) and gravity geophysical surveys under a research and development grant at the Nyngan Project.Within the immediate district Fleet Space recently completed the world's largest ANT survey, undertaking a number of project-specific surveys that defined multiple new targets and built a proprietary AI-powered district-scale copper prospectivity map 8,9,10.The Fleet Space surveys are anticipated to complement Kincora and AngloGold Ashanti's planned exploration and upcoming drilling.About KincoraKincora Copper is dual listed on the ASX and TSX-V (ticker "KCC") and is an active explorer and project generator focused on world-class copper-gold discoveries. The company recently executed four agreements that unlock up to A$60 million in multiple year partner funding. Further new projects that offer a clear value path and targeted partnerships are proposed.Kincora's portfolio includes district scale landholdings and scalable drill-ready targets in both Australia and Mongolia's leading porphyry belts, the Macquarie Arc and Southern Gobi, respectively, and, the Company is targeting initial exposure to 10,000m of drilling in the next 6-month before ramping up to over 30,000 metres pa of drilling.For more information please visit Kincora's website at www.kincoracopper.comReferences:1 Lundin Mining and BHP to Acquire Filo and Form a 50/50 Joint Venture to Progress the Filo del Sol and Josemaria Projects - BHP and Lundin Mining press releases July 29, 20242 NGEX Minerals Corporate Presentation (July 2024) and market values as at July 29, 2024 (from peer transactions and TSXV market capitalization)3 Sourced from MinEx Consulting for Kincora4 AngloGold Ashanti to earn-in to the NJNB Project - Kincora press release May 28, 20245 ANT and Gravity Geophysical Surveys at the Nyngan Project - Kincora press release July 25th, 2024 6 Inflection Resources provides drilling update from Phase 1 Exploration Program in NSW - Inflection press release July 30th, 2024 7 Kincora secures strategic license in Australia's leading porphyry belt - Kincora press release November 21, 20198 ANT geophysics defines additional epithermal-porphyry targets at Spur Project - Waratah press release May 23, 20249 Reimaging porphyry copper exploration using Exosphere: Ambient Noise Tomography from the Duck Creek project, Macquarie Fleet and Inflection Case Study 2023 10 Completes 1,800Km2 Ambient Noise Tomography Survey Across Portfolio of Projects in New South Wales - Inflection press release July 10, 2024This announcement has been authorised for release by the Board of Kincora Copper Limited (ARBN 645 457 763)For further information please contact:Sam Spring, President and Chief Executive Officersam.spring@kincoracopper.com or +61431 329 345Executive office 400 - 837 West Hastings Street Vancouver, BC V6C 3N6, Canada Tel: 1.604.283.1722 Fax: 1.888.241.5996Subsidiary office AustraliaVista AustraliaLevel 4, 100 Albert RoadSouth Melbourne, Victoria 3205Qualified PersonThe scientific and technical information in this announcement was prepared in accordance with the standards of the Canadian Institute of Mining, Metallurgy and Petroleum and National Instrument 43-101 - Standards of Disclosure for Mineral Projects ("NI 43-101") and was reviewed, verified and compiled by Kincora's staff under the supervision of Peter Leaman (M.Sc. Mineral Exploration, FAusIMM), Senior Vice-President of Exploration of Kincora, and John Holliday (BSc Hons, BEc, member of the Australian Institute of Geoscientists), Non-Executive Director and Chairman of Kincora's Technical Committee, who are Qualified Persons for the purpose of NI 43-101.JORC Competent Person StatementInformation in this announcement that relates to Exploration Results, Mineral Resources or Ore Reserves are those that have been previously reported (with the original release referred to in this announcement), in the case of Mineral Resources or Ore Reserves the material assumptions and technical parameters underpinning the estimates have not materially changed, and have been reviewed and approved by Paul Cromie, who is a Competent Person under the definition established by JORC and has sufficient experience which is relevant to the style of mineralisation and type of deposit under consideration and to the activity being undertaking to qualify as a Competent Person as defined in the 2012 Edition of the 'Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves'. John Holliday and Peter Leaman consents to the inclusion in this report of the matters based on his information in the form and context in which it appears. The review and verification process for the information disclosed herein for the Nyngan Projects have included the receipt of all material exploration data, results and sampling procedures of previous operators and review of such information by Kincora's geological staff using standard verification procedures.Forward-Looking StatementsCertain information regarding Kincora contained herein may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements may include estimates, plans, expectations, opinions, forecasts, projections, guidance or other statements that are not statements of fact. Although Kincora believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Kincora cautions that actual performance will be affected by a number of factors, most of which are beyond its control, and that future events and results may vary substantially from what Kincora currently foresees. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration results, continued availability of capital and financing and general economic, market or business conditions. The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The information contained herein is stated as of the current date and is subject to change after that date. Kincora does not assume the obligation to revise or update these forward-looking statements, except as may be required under applicable securities laws.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) or the Australian Securities Exchange accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/219846 Copyright 2024 ACN Newswire via SeaPRwire.com.

14 8 月, 2024

Experience Eternal Romance with Exquisite Blue Diamonds by ALUXE

SINGAPORE, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive "Lovers" collection. Originally launched in 2023, this exquisite wedding ring collection now embraces new designs that seamlessly blend timeless elegance with contemporary flair.ALUXE has upheld a customer-centric approach, providing each customer with the finest products and services. ALUXE is committed to crafting captivating jewellery and spreading happiness to countless couples worldwide.The 2024 collection features 8 captivating new designs, set to debut just before the Chinese Valentine’s Day. Adorned with rare and eternal blue diamonds, these pieces symbolise purity and enduring love. Inspired by bridal bouquets and veils, the designs combine simplicity with sophistication, creating unique and extraordinary works of art.Each ring in the "Lovers" collection is a testament to the purest form of love between two people. With these rings, ALUXE seeks to turn fleeting moments of happiness into cherished memories. The eternal blue diamonds in the new designs represent both purity and everlasting love, with each stone symbolising the unwavering commitment and sincerity between lovers. Every ring embodies the essence of “Every moment with you is a moment of love,” capturing the spirit of shared romantic journeys. Each ring also features a discreetly embedded blue sapphire inside, adding a touch of understated elegance.ALUXE’s exceptional craftsmanship ensures that every ring is not only beautiful but also unique. The meticulous attention to detail and superior craftsmanship provide exceptional comfort, while the minimalist design maintains a refined sophistication, making these rings perfect for any occasion.To celebrate the launch of the new collection, ALUXE is offering complimentary personalised engravings for a limited time. These bespoke engravings add a personal touch, making the rings even more special and memorable.Chinese Valentine’s Day, a day dedicated to love and promises, is the perfect occasion to introduce the new "Lovers" collection. These wedding rings are ideal for couples looking to celebrate their love and make a lifelong commitment. Let the "Lovers" collection accompanies every love story, adding a touch of romance to each chapter.Discover the new "Lovers" series at ALUXE stores or visit our website to view the complete collection. Celebrate your love with a ring that symbolises the purest and most enduring moments of your relationship.Lovers Series – The moments of loveThe "purity" of blue diamonds is like the sincere love between lovers. The " brilliance " of blue diamond’s tells the sparkle of every romantic moment. The "blue" of blue diamonds is the foundation of trust and security between lovers. Blue is both infnite and eternal. Each unique blue diamond turns the happiness between lovers into eternity. Every moment with you is the moment of love.Design Features:I am willing to walk alongside you all the way, supporting each other and shining in our own ways. The curve of the ring symbolises the love of two people running towards each other, while the blue diamond represents the figures on their growth path. Together, they grow into braver and more resilient soulmates, telling the story of a sweet and brilliant love between lovers.Lovers Collection - Blue Diamond Engagement Ring (RS2010)The curved bands on both sides extend to the centre, where the main diamond is set. Just like our love, it takes two people holding hands tightly to achieve happiness.RS2010Platinum SGD 2,520(Excluding Diamond) Lovers Collection - Blue Diamond Wedding Ring (RBG0010):The matching rings feature a streamlined design that symbolises a love journey where both sides meet each other halfway. The man's ring has a calm, brushed texture, while the woman's ring is adorned with diamonds, representing hopes and dreams for the future. The blue diamond symbolises the couple walking side by side, experiencing both joys and challenges together, each shining in their unique way.RB0010Platinum SGD 2,090RG0010Platinum SGD 2,140 Design Features:Your presence is the greatest protection for my love. Inspired by a bouquet, it elegantly cradles the main diamond. A flowing line on the ring symbolises the unique mark of love, writing the story of a steady and enduring romance between two people.Lovers Collection - Blue Diamond Engagement Ring (RS2018):The main diamond ring is designed like a bouquet, symbolising the blossoming of our love and the beginning of a new chapter in life together. The blue diamonds on either side of the main diamond represent the two of us, steadfastly protecting this miraculous love.RS2018Platinum SGD 1,980(Excluding Diamond) Lovers Collection - Blue Diamond Wedding Ring (RBG0018)A sleek, simple line on the ring band symbolises the story of our enduring love, like the unspoken understanding and eternity between us. From now on, whether in moments of brilliance or in everyday life.RB0018Platinum SGD 2,090RG0018Platinum SGD 1,770 Design Features:The blue diamond represents the most brilliant moment between us, a fleeting instant turned eternal. It carries the love memories of two people through time. As sunlight falls, it reflects our every moment of happiness and sweetness.Lovers Collection - Blue Diamond Wedding Ring (RBG0009)The blue diamond symbolises our most brilliant moment, eternal in an instant. Forever in our hearts, the ring band is like a steady shoulder, protecting that brilliant memory and expressing your unwavering and understanding love.The blue diamond captures our happiness, making a moment eternal. The row of diamonds represents the countless love memories we share over time. Worn every day, it shines with infinite beauty.RB0009Platinum SGD 2,320RG0009Platinum SGD 1,780 For Media Queries, Please Contact:Chua Sheng Rui: +65 9137 2102 // shengrui@swstrategies.orgAmirul Asyraf: +65 8448 4824 // amirul@swstrategies.orgAbout ALUXEALUXE is the first jewellery brand in Taiwan, embodying the perfect combination of happiness and jewellery. Starting as an online retailer, ALUXE's high-quality products and competitive prices gradually garnered more attention, which led to the opening of its first physical store in 2008 to offer even better products and services to customers around the world. ALUXE is currently present in Taiwan and Hong Kong, with Singapore’s flagship store located at ION Orchard and two other doors at the heartland areas.For more information, visit https://www.aluxe.com/FB: https://www.facebook.com/aluxe.sgIG: https://www.instagram.com/aluxe_sg/Whatsapp: +65 8189 7721ALUXE LocationsION Orchard2 Orchard Turn, ION Orchard #B2-63, Singapore 238801Tel: +65 6015 0798Opening Hours: 10:00 - 21:30JEM50 Jurong Gateway Road, JEM #01-55, Singapore 608549Tel: +65 6992 2589Opening Hours: 11:00 - 21:30Tampines 110 Tampines Central 1, Tampines 1 #01-27 & 28, Singapore 529536Tel: +65 6022 1715Opening Hours: 11:00 - 21:30 Copyright 2024 ACN Newswire via SeaPRwire.com.

14 8 月, 2024

Nissin Foods Becomes a Constituent of MSCI Global Micro Cap Index (MSCI Hong Kong Index)

HONG KONG, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) is pleased to announce that the Company is selected as a constituent to the MSCI Global Micro Cap Index (MSCI Hong Kong Micro Cap Index), with effect from the market close of 30 August 2024 (Friday).Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “We are confident that the Group's inclusion in the MSCI Hong Kong Micro Cap Index reflects the capital market’s appreciation of our business strategy and operational excellence. This development is anticipated to draw increased investor interest in the Group's growth prospects, potentially leading to a broader shareholder base. Looking ahead, we are actively enhancing our product portfolio and continuing to provide shareholders with greater value.”The MSCI Global Micro Cap Index captures micro cap representation across 23 developed markets countries. With 6,406 constituents, the index covers approximately 1% of the free float-adjusted market capitalization in each country. Assessments for the index are based on key factors, including minimum market capitalization, free float and liquidity, foreign inclusion factor requirement, and minimum length of trading requirement.- End -About Nissin Foods Company LimitedNissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and Mainland China, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN” and “DOLL” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Mainland China market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first-and second-tier cities. In addition, Nissin Foods operates business in other Asian regions including Vietnam, Taiwan and Korea markets.Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Consumer Staples Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk. Copyright 2024 ACN Newswire via SeaPRwire.com.

14 8 月, 2024

踏上巴黎高訂殿堂香港設計師Robert Wun 首度「回家」呈獻時裝騷

香港, 2024年8月13日 - (亞太商訊 via SeaPRwire.com) – 由香港貿易發展局 （香港貿發局） 主辦、文創產業發展處資助的亞洲時裝界年度盛事 CENTRESTAGE（香港國際時尚匯展），將於9月4至7日（星期三至星期六）假香港會議展覽中心隆重舉行，而開幕時裝騷CENTRESTAGE ELITES會於展會前一天（9月3日）假香港故宮文化博物館華麗上演。今屆CENTRESTAGE ELITES邀請到首位躋身巴黎高級訂製時裝周的香港時裝設計師 Robert Wun（雲惟駿）參與，他將以Home作為是次時裝騷主題。這將是Robert Wun 首次回歸香港的時裝騷，亦是香港故宮文化博物館首度上演時裝表演；觀眾將走過博物館標誌性的朱紅色大門進入會場，開展一段非凡的旅程。 Robert Wun 表示：「我的時裝設計師夢想在香港萌芽，這次回來香港舉辦時裝騷，令我過去十年的經歷、點滴、堅持和回憶都重新浮現出来。香港對我有著重要的影響，香港人的精神帶動我對工作充滿熱誠和魄力，我也承傳這裡的文化，擁有一顆感恩的心，飲水思源，適逢品牌十周年，我決定回來辦這個騷；而這場騷的設計和演繹，包含了一些我們（香港人）看得懂的元素。」他又預告：「我藉著新系列向嫲嫲致敬，設計靈感主要是來自香港女性不屈、勤勞的精神，及多才多藝的特點，還有我們文化上剛柔並重的感覺。我從香港的音樂、影視劇集及電影均得到不少啟發。」Robert Wun透露，在CENTRESTAGE ELITES中，除了會呈獻多套融入香港文化及情懷的嶄新設計之外，亦會重現他過去十年創作的經典作品，見證他圓滿回歸香港的重要時刻。展會分享大師心得Robert Wun於香港出生，2012年在倫敦時裝學院發表畢業設計系列時，被香港知名時裝集團Joyce Boutique發掘。他其後在2014年創立其同名品牌。Robert Wun的卓越成就得到各界認同，於2020年獲選為Fashion Asia Hong Kong* 10 Asian Designers To Watch之一；2022年榮獲 ANDAM Fashion Awards Prix Spécial 特別獎，並在2023年獲《Vogue Business 100》和《Tatler Asia》評選為時尚圈最具影響力人物之一。2023年1月，Robert Wun首次亮相巴黎時裝周，獲CHANEL總裁Bruno Pavlovsky大力支持，在時裝周的閉幕時裝騷發佈他的首個高級訂製服系列。Robert Wun的作品受到國際頂尖明星青睞，包括Beyoncé、Celine Dion、Lady Gaga、Adele、Cardi B、Florence Pugh 和 Billy Porter。此外，他亦曾為英國皇家芭蕾舞團、電影《飢餓遊戲》以及王家衛導演的電視廣告等設計服飾。（*文創產業發展處資助）Robert Wun成為國際頂尖時裝設計師的歷程極富啟發性，他將於CENTRESTAGE展會第二天（9月5日）主持大師分享會，分享其創作心得和心路歷程。與此同時，展會上亦會展出其別具匠心的設計。CENTRESTAGE是推廣環球設計師品牌及系列的亞洲時尚盛事，同時亦是區內時尚品牌發佈及推廣新系列和產品的理想平台。香港貿發局今年繼續邀請來自世界各地的業界人士到場參觀採購，並安排商貿配對活動，促進合作商機。一如過往，連場精彩活動，包括時裝表演、研討會、交流活動、時裝巡禮、香港青年時裝設計家創作表演賽等，將令與會者及觀眾收穫豐富、目不暇給。有關詳情將於8月20日於香港故宮文化博物館舉行的記者會公佈。圖片下載：https://bit.ly/3WP9hO2傳媒聯絡Best Crew Public Relations & Marketing鄧麗兒電話：(852) 9199 6723電郵：diana.tang@bestcrewpr.com郭穎軒電話：(852) 6291 4283電郵：reni.kwok@bestcrewpr.com香港貿發局傳訊及公共事務部：陳施樂 電話：(852) 2584 4537電郵：snowy.sn.chan@hktdc.org香港貿發局新聞中心︰http://mediaroom.hktdc.com/tc香港貿易發展局簡介香港貿易發展局(香港貿發局)是於1966年成立的法定機構，負責促進、協助和發展香港貿易。香港貿發局在世界各地設有50個辦事處，其中13個設於內地，致力推廣本港作為雙向環球投資及商業樞紐。 香港貿發局通過舉辦國際展覽會、會議及商貿考察團，為企業(尤其是中小企)開拓內地和環球市場的機遇。香港貿發局亦通過研究報告和數碼資訊平台，提供最新的市場分析和產品資訊。有關香港貿發局的其他資訊，請瀏覽www.hktdc.com/aboutus/tc。請關注我們的 @香港貿發局 @香港貿發局時尚生活 @香港商貿通 香港貿發局 請訂閱香港貿發局文創產業發展處簡介文創產業發展處於2024年6月成立，前身為「創意香港」，是香港特別行政區政府文化體育及旅遊局轄下專責為文化和創意業界提供一站式服務與支援的辦公室，致力為香港營造有利的環境，促進藝術、文化及創意業界的產業化發展。現時的策略重點為培育人才及促進初創企業的發展、開拓市場、推動更多跨界別、跨文化藝術領域的合作、推動文化藝術和創意業界產業化發展，以及推動香港成為亞洲創意之都，並在社會營造創意氛圍，以落實國家《十四五規劃綱要》下香港作為中外文化藝術交流中心的定位。網址：https://www.ccidahk.gov.hk。Fashion Hong Kong 簡介Fashion Hong Kong 是香港貿易發展局（香港貿發局）推廣香港時裝設計的活動，銳意帶領香港時裝設計師及品牌連繫國際市場。香港貿發局將於 9月3日CENTRESTAGE ELITES時裝表演當天，在香港故宮文化博物館地下展出10位今屆Fashion Hong Kong設計師的作品，並會於9月4日在香港會議展覽中心舉辦Fashion Hong Kong Runway Show。 Fashion Hong Kong Runway Show 由香港貿發局主辦、文創產業發展處資助，將由導演陳志發執導，以電影手法呈獻四個香港時裝品牌ANGUS TSUI、röyksopp gakkai、selfFab.、Z I D I 的全新2025 春夏系列作品。展會網頁CENTRESTAGE 展會網頁：www.centrestage.com.hkCENTRESTAGE ELITES網頁：http://www.hktdc.com/event/centrestage/tc/centrestage-elitesFashion Hong Kong 網頁：https://www.fashionhongkong.com.hk/tc香港青年時裝設計家創作表演賽(YDC)網頁：www.fashionally.com/zh-hk/免責聲明：香港特別行政區政府僅為本項目提供資助，除此之外並無參與項目。在本刊物／活動內（或由項目小組成員）表達的任何意見、研究成果、結論或建議，均不代表香港特別行政區政府、文化體育及旅遊局、文創產業發展處、「創意智優計劃」秘書處或「創意智優計劃」審核委員會的觀點。 Copyright 2024 亞太商訊 via SeaPRwire.com.

14 8 月, 2024

Experience Eternal Romance with Exquisite Blue Diamonds

SINGAPORE, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive "Lovers" collection. Originally launched in 2023, this exquisite wedding ring collection now embraces new designs that seamlessly blend timeless elegance with contemporary flair.ALUXE has upheld a customer-centric approach, providing each customer with the finest products and services. ALUXE is committed to crafting captivating jewellery and spreading happiness to countless couples worldwide.The 2024 collection features 8 captivating new designs, set to debut just before the Chinese Valentine’s Day. Adorned with rare and eternal blue diamonds, these pieces symbolise purity and enduring love. Inspired by bridal bouquets and veils, the designs combine simplicity with sophistication, creating unique and extraordinary works of art.Each ring in the "Lovers" collection is a testament to the purest form of love between two people. With these rings, ALUXE seeks to turn fleeting moments of happiness into cherished memories. The eternal blue diamonds in the new designs represent both purity and everlasting love, with each stone symbolising the unwavering commitment and sincerity between lovers. Every ring embodies the essence of “Every moment with you is a moment of love,” capturing the spirit of shared romantic journeys. Each ring also features a discreetly embedded blue sapphire inside, adding a touch of understated elegance.ALUXE’s exceptional craftsmanship ensures that every ring is not only beautiful but also unique. The meticulous attention to detail and superior craftsmanship provide exceptional comfort, while the minimalist design maintains a refined sophistication, making these rings perfect for any occasion.To celebrate the launch of the new collection, ALUXE is offering complimentary personalised engravings for a limited time. These bespoke engravings add a personal touch, making the rings even more special and memorable.Chinese Valentine’s Day, a day dedicated to love and promises, is the perfect occasion to introduce the new "Lovers" collection. These wedding rings are ideal for couples looking to celebrate their love and make a lifelong commitment. Let the "Lovers" collection accompanies every love story, adding a touch of romance to each chapter.Discover the new "Lovers" series at ALUXE stores or visit our website to view the complete collection. Celebrate your love with a ring that symbolises the purest and most enduring moments of your relationship.Lovers Series – The moments of loveThe "purity" of blue diamonds is like the sincere love between lovers. The " brilliance " of blue diamond’s tells the sparkle of every romantic moment. The "blue" of blue diamonds is the foundation of trust and security between lovers. Blue is both infnite and eternal. Each unique blue diamond turns the happiness between lovers into eternity. Every moment with you is the moment of love.Design Features:I am willing to walk alongside you all the way, supporting each other and shining in our own ways. The curve of the ring symbolises the love of two people running towards each other, while the blue diamond represents the figures on their growth path. Together, they grow into braver and more resilient soulmates, telling the story of a sweet and brilliant love between lovers.Lovers Collection - Blue Diamond Engagement Ring (RS2010)The curved bands on both sides extend to the centre, where the main diamond is set. Just like our love, it takes two people holding hands tightly to achieve happiness.RS2010Platinum SGD 2,520(Excluding Diamond) Lovers Collection - Blue Diamond Wedding Ring (RBG0010):The matching rings feature a streamlined design that symbolises a love journey where both sides meet each other halfway. The man's ring has a calm, brushed texture, while the woman's ring is adorned with diamonds, representing hopes and dreams for the future. The blue diamond symbolises the couple walking side by side, experiencing both joys and challenges together, each shining in their unique way.RB0010Platinum SGD 2,090RG0010Platinum SGD 2,140 Design Features:Your gentleness is my greatest safeguard in this life. Inspired by a bouquet, it elegantly cradles the main diamond. A flowing line on the ring symbolises the unique mark of love, writing the story of a steady and enduring romance between two people.Lovers Collection - Blue Diamond Engagement Ring (RS2018):The main diamond ring is designed like a bouquet, symbolising the blossoming of our love and the beginning of a new chapter in life together. The blue diamonds on either side of the main diamond represent the two of us, steadfastly protecting this miraculous love.RS2018Platinum SGD 1,980(Excluding Diamond) Lovers Collection - Blue Diamond Wedding Ring (RBG0018)A sleek, simple line on the ring band symbolises the story of our enduring love, like the unspoken understanding and eternity between us. From now on, whether in moments of brilliance or in everyday life.RB0018Platinum SGD 2,090RG0018Platinum SGD 1,770 Design Features:The blue diamond represents the most brilliant moment between us, a fleeting instant turned eternal. It carries the love memories of two people through time. As sunlight falls, it reflects our every moment of happiness and sweetness.Lovers Collection - Blue Diamond Wedding Ring (RBG0009)The blue diamond symbolises our most brilliant moment, eternal in an instant. Forever in our hearts, the ring band is like a steady shoulder, protecting that brilliant memory and expressing your unwavering and understanding love.The blue diamond captures our happiness, making a moment eternal. The row of diamonds represents the countless love memories we share over time. Worn every day, it shines with infinite beauty.RB0009Platinum SGD 2,320RG0009Platinum SGD 1,780 For Media Queries, Please Contact:Chua Sheng Rui: +65 9137 2102 // shengrui@swstrategies.orgAmirul Asyraf: +65 8448 4824 // amirul@swstrategies.orgAbout ALUXEALUXE is the first jewellery brand in Taiwan, embodying the perfect combination of happiness and jewellery. Starting as an online retailer, ALUXE's high-quality products and competitive prices gradually garnered more attention, which led to the opening of its first physical store in 2008 to offer even better products and services to customers around the world. ALUXE is currently present in Taiwan and Hong Kong, with Singapore’s flagship store located at ION Orchard and two other doors at the heartland areas.For more information, visit https://www.aluxe.com/FB: https://www.facebook.com/aluxe.sgIG: https://www.instagram.com/aluxe_sg/Whatsapp: +65 8189 7721ALUXE LocationsION Orchard2 Orchard Turn, ION Orchard #B2-63, Singapore 238801Tel: +65 6015 0798Opening Hours: 10:00 - 21:30JEM50 Jurong Gateway Road, JEM #01-55, Singapore 608549Tel: +65 6992 2589Opening Hours: 11:00 - 21:30Tampines 110 Tampines Central 1, Tampines 1 #01-27 & 28, Singapore 529536Tel: +65 6992 2589Opening Hours: 11:00 - 21:30 Copyright 2024 ACN Newswire via SeaPRwire.com.

14 8 月, 2024

Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results

Development Highlights- During the reporting Period, four of the Group’s innovative products were approved for marketing by the National Medical Products Administration of China (“NMPA”), namely Andewei (Benmelstobart Injection), Anboni (Unecritinib capsules), Anluoqing (Envonalkib capsules) and Beilelin (Liraglutide Injection), three of which are national category 1 innovative drugs.- In the first half of 2024, the Group's revenue from innovative products reached RMB 6.13 billion, a year-on-year increase of 14.8%. In addition to innovative products, the Group has 11 generic drugs approved by the NMPA for market launch. The overall revenue of generic drugs achieved positive growth in the first half of 2024. New products are an important driver of the Group’s revenue growth. In the first half of 2024, the Group’s revenue from new products launched within five years reached RMB 6.03 billion, representing a year-on-year increase of 39.6%.- As of 30 June 2024, the Group had a total of 43 innovative drug candidates in the field of oncology, 8 innovative drug candidates related to the respiratory system, 6 innovative drug candidates related to liver disease, and 4 innovative drug candidates in the field of surgery/analgesia in the process of clinical trial application or above. Of these, 3 innovative oncology drug candidates and 1 innovative surgery/analgesia drug candidate are in the marketing application stage, and 5 innovative oncology drug candidates, 1 innovative respiratory system drug candidate, 1 innovative liver disease drug candidate, and 1 innovative surgery/analgesia drug candidates are in Phase III clinical trials. In addition, the Group had a total of 18 biosimilar or generic drug oncology candidates, 3 additional biosimilar or generic liver disease drug candidates, 21 biosimilar or generic respiratory system drug candidates, and 10 biosimilar or generic surgical/analgesic drug candidates in the clinical trial application or above.- Focus V (Anlotinib Hydrochloride Capsules) is a new type of small molecule multi-target tyrosine kinase inhibitor. In February and July 2024, for anlotinib in combination with benmelstobart, two marketing applications were submitted to the Center for Drug Evaluation (“CDE”) of NMPA for the treatment of second- and third-line endometrial cancer, and first line renal cell carcinoma, respectively. In July 2024, the Phase III clinical study of anlotinib in combination with chemotherapy for the first-line treatment of advanced soft tissue sarcoma achieved positive results. The Group has submitted the marketing application and received acceptance for the new indication.- Yilishu (Efbemalenograstim Alfa Injection) was approved in May 2023 for the prevention and treatment of neutropenia in cancer patients taking chemotherapy drugs. In December 2023, Efbemalenograstim alfa was successfully included in the National Reimbursement Drug List (“NRDL”), and its sales volume accelerated in the first half of 2024, becoming an important contributor to the Group’s revenue growth.- Andewei (Benmelstobart Injection) is a humanized PD-L1 monoclonal antibody that was approved by the NMPA in April 2024 for use in combination with anlotinib, carboplatin, and etoposide in the first-line treatment of extensive-stage small cell lung cancer.- Anboni (Unecritinib Fumarate Capsules) is a small molecule inhibitor of tyrosine kinase ROS1/ALK/c-Met, which was approved by the NMPA in April 2024 for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer. It is the first domestically produced targeted drug approved for the treatment of ROS1-positive non-small cell lung cancer.- The clinical trial application of Lanifibranor was submitted to and accepted by CDE in March 2023. In July, Lanifibranor was included in the list of breakthrough therapeutics. Currently, Lanifibranor is conducting Phase III clinical trials globally and is actively advancing the enrollment of subjects. Lanifibranor is China's first oral MASH drug to enter Phase III clinical trials and is expected to fill the gap in China's MASH market.HONG KONG, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2024 (the “Period”).During the Period, the Group recorded revenue of approximately RMB15.87 billion, a year-on-year increase of approximately 11.1%. Profit attributable to owners of the parent company was approximately RMB3.02 billion, a year-on-year increase of approximately 139.7%. Earnings per share attributable to owners of the parent company were approximately RMB16.39 cents. The significant year-over-year increase in profit attributable to owners of the parent company was mainly due to the gain on disposal of subsidiaries under discontinued operations during the current Period. Adjusted non-HKFRS profit attributable to the owners of the parent was approximately RMB1.54 billion, a YOY increase of approximately 14.0%. The Group's liquidity remains strong, with cash and bank balances classified as current assets of approximately RMB8.55 billion, bank deposits classified as non-current assets of approximately RMB9.18 billion, and wealth management products of approximately RMB4.61 billion in total, and total fund reserves amounting to approximately RMB22.34 billion at the end of the Period.The Board of Directors has recommended an interim dividend payment of HK3 cents per share (1H2023: HK2 cents).Miss Tse, Theresa Y Y, Executive Director and ChairwomanSales: Entering harvesting of innovative results period and sales revenue from generic products further risesAlways placing utmost importance on research and development (“R&D”), the Group leverages in-depth research and development to achieve significant benefits. At present, the Group has entered the harvest period of its innovative development, driving further growth in sales revenue. During the Period, sales of oncology drugs increased by 19.5% year-on-year to approximately RMB5.36 billion, accounting for approximately 33.8% of the Group's revenue. Sales of surgical/analgesic medications increased by 29.9% year-on-year to approximately RMB2.58 billion, accounting for approximately 16.3% of the Group's revenue. Sales of liver disease drugs amounted to approximately RMB2.03 billion, accounting for approximately 12.8% of the Group's revenue. In addition, the sales contributions of products in various areas such as respiratory system, cardio-cerebral vascular medicines, and others increased simultaneously, accounting for approximately 11.2%, 8.6%, and 17.3% of the Group's total revenue, respectively.In the field of respiratory system, The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the volume-based procurement (VBP), enabling Tianqing Suchang’s sales to achieve steady growth during the Period. In the meanwhile, the Group continued to expand its market coverage through active academic promotion, and Tianyun’s sales grew rapidly during the Period.In the field of surgery/analgesia, the Group focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand. Sales of flurbiprofen cataplasms have maintained a growth trend in recent years and achieved breakthrough growth during the Period.Mr. Tse, Eric S Y, Executive Director and Chief Executive OfficerR&D: R&D as the core for driving the Group's continuous innovation and developmentThe Group has continued to focus its R&D efforts on new medicines in the four therapeutic areas of oncology, liver disease, respiratory system and surgery/analgesia. As at the end of the reporting Period, the Group had 76 innovative products in development, including 46 oncology products, 6 liver disease products, 9 respiratory system products, 5 surgery/analgesia products, and 10 other products. In addition, the Group had 65 generic drug products in development.The Group has always put R&D at its core, and has continuously improved its R&D capabilities and speed by embracing the R&D concept of combining independent innovation, collaborative development, and the development of both innovative and generic drugs. It considers R&D as the foundation of its sustainable development. In the first half of 2024, it incurred R&D expenses of approximately RMB 2.58 billion, accounting for approximately 16.2% of the Group’s revenue. It is expected that the number of innovative products launched to the market will reach 25 by 2026. This will further strengthen the Group’s dominant position in the four main therapeutic areas and provide strong impetus for long-term sustainable growth.Sino Biopharmaceutical ManagementProspects: Keep up with national development strategy and accelerate globalization processThe pharmaceutical industry has become one of the fastest growing and most promising fields in China and even the world. As the world’s second largest pharmaceutical market, China’s demand for medical and healthcare products has grown rapidly in recent years, with breakthroughs being made in biotechnology. Innovation has become a new driving force for the high-quality development of China’s pharmaceutical industry. The Group has been closely monitoring the development of the country, society and the industry, and has continuously optimized its development strategy. Under the four main strategies of “organizational integration, comprehensive innovation, internationalization, and digitalization”, the Group will actively innovate its organizational structure, comprehensively improve its operational efficiency, focus on the innovation and development of the four main therapeutic areas of oncology, liver disease, respiratory system, and surgery/analgesia, and actively accelerate the global deployment of its business.The Group is committed to its mission of becoming a “leading global pharmaceutical company through delivering innovative therapies for patients”. It strives to promote innovative development through its dual engines of internal R&D and business development. Over the years, the Group has stepped up its R&D investment and built strong internal R&D capabilities. At the same time, it has vigorously promoted business development and strategic cooperation, striving to become the best partner for global pharmaceutical and biotechnology enterprises. In April 2024, the Group entered into a strategic partnership with Boehringer Ingelheim to bring Boehringer Ingelheim's innovative cancer therapies to the Mainland Chinese market. This move not only demonstrates The Group's innovative strength in the pharmaceutical field, but also reflects its far-reaching influence in international cooperation.Looking ahead, The Group will adhere to its dual-pronged approach in the implementation of its globalization strategy. Through this approach, the Group will bring global pharmaceutical innovations to China to benefit Chinese patients, and also go global and open up new markets to accelerate the satisfaction of unmet clinical needs worldwide. Copyright 2024 ACN Newswire via SeaPRwire.com.

14 8 月, 2024

中國生物製藥（1177.HK）公佈2024中期業績

重點成果- 期內，集團共有4個創新產品獲中國國家藥品監督管理局（「NMPA」）批准上市，分別為安得衛（貝莫蘇拜單抗注射液）、安柏尼（富馬酸安奈克替尼膠囊）、安洛晴（枸櫞酸依奉阿克膠囊）和貝樂林（利拉魯肽注射液），其中3個為國家1類創新藥。- 2024年上半年，集團創新產品收入達到61.3億元，同比增長14.8%。除創新產品外，集團還有11個仿製藥獲NMPA批准上市，整體仿製藥收入在2024年上半年已實現正增長。新產品是驅動集團收入增長的重要動力，2024年上半年集團5年內上市的新產品收入達到60.3億元，同比增長39.6%。- 截至2024年6月30日，集團共有43個腫瘤領域、8個呼吸系統領域、6個肝病領域和4個外科╱鎮痛領域的創新候選藥物處於臨床申請及以上開發階段。其中，3個腫瘤領域、1個外科╱鎮痛領域產品處在上市申請階段；5個腫瘤領域、1個呼吸系統領域、1個肝病領域、1個外科╱鎮痛領域的創新候選藥物處於臨床III期；另有18個腫瘤領域、3個肝病領域、21個呼吸系統領域、10個外科╱鎮痛領域的生物類似藥或仿製藥候選藥物處於臨床申請及以上開發階段。- 福可維（鹽酸安羅替尼膠囊）是一種新型小分子多靶點酪氨酸激酶抑制劑。2024年2月和7月，安羅替尼聯合貝莫蘇拜單抗向中國國家藥品監督管理局藥品審評中心（「CDE」）遞交兩項新適應症上市申請，分別用於治療二三線子宮內膜癌和一線腎細胞癌。2024年7月，安羅替尼聯合化療用於晚期軟組織肉瘤一線治療的III期臨床研究取得陽性結果，集團已遞交新適應症上市申請並獲受理。- 億立舒（艾貝格司亭α）注射液於2023年5月獲批用於預防和治療腫瘤患者在接受化療藥物後出現的中性粒細胞減少症。2023年12月，億立舒被成功納入國家醫保目錄，並在2024年上半年加速放量，成為集團收入增長的重要貢獻品種。- 安得衛（貝莫蘇拜單抗注射液）是一款人源化PD-L1單克隆抗體，於2024年4月獲得NMPA的上市批准，用於聯合安羅替尼、卡鉑和依託泊甘一線治療廣泛期小細胞肺癌。- 安柏尼（富馬酸安奈克替尼膠囊）是一款酪氨酸激酶ROS1/ALK/c-Met小分子抑制劑，於2024年4月獲得NMPA的上市批准，用於治療ROS1陽性的局部晚期或轉移性非小細胞肺癌，是首個獲批用於治療ROS1陽性非小細胞肺癌的國產靶向藥。- 拉尼蘭諾（泛PPAR激動劑）於2023年3月向CDE遞交臨床試驗申請並獲得受理，7月，拉尼蘭諾被CDE納入突破性治療品種名單。目前該產品正在全球進行III期臨床試驗，是中國第一個進入臨床III期的MASH口服藥物，有望填補中國MASH市場空白。香港, 2024年8月14日 - (亞太商訊 via SeaPRwire.com) – 中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公佈截至2024年6月30日止6個月（「期內」）之未經審核財務業績。回顧期內，集團收入同比增長11.1%至約158.7億元（人民幣，下同）。歸屬於母公司持有者應佔盈利約30.2億元，同比增長約139.7%，基於歸屬於母公司持有者應佔盈利計算之每股盈利約16.39分。歸屬於母公司持有者盈利同比顯著增加主要由於本期間錄得處置附屬公司收益並計入已終止經營業務導致。經調整非《香港財務報吿準則》歸母淨利潤約15.4億元，同比增長約14.0%。集團流動資金保持充裕，期內有計入流動資產之現金及銀行結餘約85.5億元、計入非流動資產之銀行存款約91.8億元，理財管理產品總額約46.1億元，資金儲備合共約223.4億元。董事會建議派發中期股息每股3港仙（2023上半年：2港仙）。中國生物製藥董事會主席謝其潤女士銷售：邁入創新成果收穫期 創新產品銷售收入持續增加集團一直以來重視研發，並憑藉高研發投入以獲得顯著收益。集團現已步入創新成果密集收穫期，帶動銷售收入進一步增長。期內，抗腫瘤用藥之收入同比增加19.5%，達約53.6億元，佔集團收入約33.8%。外科／鎮痛用藥之收入同比增加29.9%，達約25.8億元，佔集團收入約16.3%。肝病用藥收入錄得約20.3億元，佔集團收入12.8%。此外，呼吸系統、心腦血管用藥和其他等不同領域產品的銷售貢獻多輪並進，分別佔集團收入約11.2%、8.6%和17.3%。於呼吸系統領域，集團及時採取了一系列主動管理措施，包括管道下沉、拓展市場覆蓋和集採外市場的二次開發，使天晴速暢銷售額於期內實現了穩步增長。同時，集團通過積極的學術推廣，不斷拓展市場覆蓋，令天韻的銷售額於期內亦取得快速增長。於外科╱鎮痛領域，集團聚焦高潛地區開發，深入拓展市場覆蓋，並逐步擴大產能，以滿足市場的旺盛需求。氟比洛芬凝膠貼膏的銷售額在過去幾年保持增長態勢，並在期內實現了突破性增長。中國生物製藥董事會首席執行長謝承潤先生研發：以研發為核心，驅動集團持續創新與發展集團繼續專注腫瘤、肝病、呼吸系統和外科╱鎮痛四大治療領域的新產品研發。截至報告期日，集團有在研創新產品76個，其中腫瘤用藥46個、肝病用藥6個、呼吸系統用藥9個、外科╱鎮痛用藥5個，其他類用藥10個。另外，集團還有65個在研仿製藥產品。集團始終將研發置於核心位置，秉承自主創新、聯合開發及創仿開發相結合的研發策略，持續提高研發能力和效率，將其視為企業持續發展的關鍵。2024年上半年集團研發費用達到約25.8億元，佔集團收入約16.2%。預計到2026年，已上市創新産品的數量將達到25個，將進一步強化集團在四大治療領域的優勢地位，爲長期可持續增長注入強大動力。中國生物製藥管理層展望：緊跟國家發展戰略，加速國際化進程醫藥行業已成為中國乃至全球最具活力和發展潛力的領域之一。中國作為全球第二大醫藥市場，近年來醫療健康需求的快速增長和生物技術的持續突破，為醫藥產業的高質量發展注入了新動力。集團緊跟國家、社會及行業的最新動態，不斷優化發展策略，以「組織整合、全面創新、國際化、數字化」為四大戰略方向，積極革新組織架構，全面提升運營效率，專注於腫瘤、肝病、呼吸、外科/鎮痛四大治療領域的創新發展，並大力推進國際化佈局。集團秉承「專注創新、服務病患，成為全球領先的製藥企業」的願景，通過自主研發和商務拓展的雙引擎驅動，不斷推動創新發展。集團不斷加大研發投入，積累了強大的自主研發能力。同時，集團積極推進商務拓展和戰略合作，力爭成為全球製藥與生物科技公司的的最佳合作夥伴。2024年4月，集團與勃林格殷格翰建立戰略合作夥伴關係，將勃林格殷格翰的創新抗腫瘤療法引入中國大陸市場，這一舉措不僅展現了集團在醫藥領域的創新實力，也體現了其在國際合作中的深遠影響力。展望未來，集團將持續堅守「引進來」與「走出去」的雙重策略，以實現國際化發展。集團將全球的醫藥創新成果引入中國，為中國的病患帶來福祉；同時也將積極開拓新的市場，以加速滿足全球各地未被滿足的臨床需求。 Copyright 2024 亞太商訊 via SeaPRwire.com.

14 8 月, 2024